Skip to main navigation Skip to main content

CMH : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Page Path

17
results for

"Ju Hyun Shim"

Article category

Keywords

Publication year

"Ju Hyun Shim"

CMH Bulletin

The Liver Week 2025 Highlights: Celebrating the 30th Anniversary of the Korean Association for the Study of the Liver
Young Eun Chon, Ju Hyun Shim, Joo Hyun Oh, Jiwon Yang, Hyunjae Shin, Wonseok Kang, Yeongseok Hwang, Su Jong Yu, Jongman Kim, Hae Won Lee, Yoon Jun Kim, Sook-Hyang Jeong
Clin Mol Hepatol 2025;31(4):1107-1114.
Published online October 1, 2025
DOI: https://doi.org/10.3350/cmh.2025.1062
  • 1,066 View
  • 41 Download

Review

Tumor-based biomarkers and circulating tumor DNA for precision medicine in advanced hepatocellular carcinoma
Sabrina Sidali, Claudia Campani, Jihyun An, Ju Hyun Shim, Jean-Charles Nault
Received July 8, 2025  Accepted August 18, 2025  Published online August 20, 2025  
DOI: https://doi.org/10.3350/cmh.2025.0746    [Accepted]
Hepatocellular carcinoma (HCC) is the most common primary liver cancer and remains a major cause of cancer-related mortality worldwide. Systemic therapies, including targeted therapies and immune checkpoint inhibitors (ICIs), have revolutionized the management of advanced HCC. Although the prognosis of patients with advanced HCC remains poor, significant progress has been made with recent advances in drug development, particularly with the introduction of effective treatments such as atezolizumab plus bevacizumab or durvalumab plus tremelimumab. Indeed, treatment response varies significantly among patients, highlighting the need for robust biomarkers. In addition, the development of molecular driver-targeted therapies remains an active research focus as most genetic alterations observed in HCC are currently undruggable. Meeting these goals will require additional efforts to obtain histological material in clinical trials, in order to enable robust translational research. This review explores the current landscape of biomarkers of response to systemic treatments in HCC, including molecular, immune-based markers as well as circulating tumor DNA and highlights potential paths of improvement.
  • 2,238 View
  • 79 Download

Original Articles

Viral hepatitis

Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide
Hyeyeon Hong, Won-Mook Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Jonggi Choi
Clin Mol Hepatol 2024;30(1):49-63.
Published online November 20, 2023
DOI: https://doi.org/10.3350/cmh.2023.0328
Background/Aims
Tenofovir disoproxil fumarate (TDF) is known to have a lipid-lowering effect. This is in contrast to tenofovir alafenamide (TAF), which has a lipid-neutral effect. Therefore, concerns have been raised as to whether these differences affect long-term cardiovascular risk. Here, we aimed to evaluate the long-term risk of cardiovascular events in chronic hepatitis B (CHB) patients treated with TAF or TDF.
Methods
We retrospectively analyzed 4,124 treatment-naïve CHB patients treated with TDF (n=3,186) or TAF (n=938) between 2012 and 2022. The primary outcome was a composite endpoint of major adverse cardiovascular events (MACE), including myocardial infarction, ischemic stroke, and hospitalization for unstable angina or heart failure. Serial changes in lipid profiles between two treatments were also explored.
Results
The median age of the patients was 50.6 years, and 60.6% of the patients were male. At baseline, 486 (11.8%) and 637 (15.4%) of the patients had dyslipidemia and fatty liver, respectively. A total of 42 MACE occurred, with an annual incidence of 0.2%/100 person-years (PYs). At 1, 3, and 5 years, the cumulative risk of MACE was 0.4%, 0.8%, and 1.2% in patients treated with TDF, and 0.2%, 0.7%, and 0.7% in patients treated with TAF, respectively (p=0.538). No significant differences in the risk of MACE were observed between TDF and TAF. A multivariable analysis found that current smoker and a history of cardiovascular events were risk factors associated with an increased risk of MACE.
Conclusions
Patients treated with TAF had comparable risks of cardiovascular outcomes, defined as MACE, as patients treated with TDF.

Citations

Citations to this article as recorded by  Crossref logo
  • Evaluating fracture risk with TDF in elderly patients with hepatitis B: A Korean perspective
    Yoon E. Shin, Jae Young Kim, Jeong Ju Yoo, Sang Gyune Kim, Young Seok Kim
    Journal of Hepatology.2025; 82(6): e301.     CrossRef
  • Tenofovir Disoproxil Fumarate Versus Entecavir: Effects on Lipid Profiles and Cardiovascular Outcomes in People Living With Chronic Hepatitis B
    Log Young Kim, Jae Young Kim, Jeong‐Ju Yoo, Sang Gyune Kim, Young‐Seok Kim
    Journal of Medical Virology.2025;[Epub]     CrossRef
  • Safety of tenofovir alafenamide in the context of hyperlipidemia and cardiovascular diseases: a nationwide analysis
    Jae-Young Kim, Hyuk Kim, Jeong-Ju Yoo, Sang Gyune Kim, Young-Seok Kim
    Hepatology International.2025; 19(4): 959.     CrossRef
  • Impact of Tenofovir Alafenamide on Lipid Profiles in Chronic Hepatitis B Patients: Systematic Review and Meta‐Analysis
    Ping‐Yu Hsu, Hui‐Chen Su, Mi‐Chia Ma, Chien‐An Chen, Sin‐Yi Yu, Yi‐Ming Hua
    Journal of Medical Virology.2025;[Epub]     CrossRef
  • Effect of switching from prior Nucleos(t)ide Analogue(s) to Tenofovir alafenamide on lipid profile and cardiovascular risk in patients with Chronic Hepatitis B
    Witchayaporn Praguylertluck, Apichat Kaewdech, Naichaya Chamroonkul, Teerha Piratvisuth, Pimsiri Sripongpun, Tyng-Yuan Jang
    PLOS One.2025; 20(5): e0324897.     CrossRef
  • Metabolic effects and cardiovascular disease risks of TDF or TAF in patients with chronic hepatitis B: a systematic review and meta-analysis
    Yuan-Hai Zhou, Nan Cai, Yu-Xin Chen, Yong-Lu Su, Peng Hu
    Frontiers in Pharmacology.2025;[Epub]     CrossRef
  • Tenofovir alafenamide-related hyperlipidemia and cardiovascular risk
    Ankur Jindal, Manoj Kumar
    Hepatology International.2025; 19(4): 701.     CrossRef
  • Comparison of bone mineral density changes between denosumab and bisphosphonates in tenofovir-exposed chronic hepatitis B patients with osteoporosis
    Yunmi Ko, Byeong Geun Song, Hyunjae Shin, Youngsu Park, Jeayeon Park, Min Kyung Park, Yun Bin Lee, Su Jong Yu, Dong Hyun Sinn, Yoon Jun Kim, Jung-Hwan Yoon, Seung Shin Park, Moon Haeng Hur, Jeong-Hoon Lee
    Osteoporosis International.2025; 36(8): 1391.     CrossRef
  • Blood pressure and metabolic outcomes after efavirenz‐ or dolutegravir‐based therapy started in acute HIV infection
    Phillip Chan, Sarah Moreland, Carlo Sacdalan, Donn J. Colby, Ferron Ocampo, Pathariya Promsena, Somchai Sriplienchan, Jarawee Wattana, Jintana Intasan, Nittaya Phanuphak, Sandhya Vasan, Robert Paul, Lydie Trautmann, Serena Spudich, Eugène Kroon
    HIV Medicine.2025; 26(10): 1619.     CrossRef
  • Efficacy and Safety of Tenofovir Alafenamide (TAF) and Tenofovir Disoproxil Fumarate (TDF) Followed by TAF in Chronic Hepatitis B Patients of East Asian Ethnicity Following 5 Years of Treatment
    Grace Lai‐Hung Wong, Edward Gane, Calvin Q. Pan, Scott Fung, Mang M. Ma, Namiki Izumi, Shalimar, Seng Gee Lim, Wan‐Long Chuang, Rajiv Mehta, Young‐Suk Lim, Leland J. Yee, John F. Flaherty, Frida Abramov, Hongyuan Wang, Maria Buti
    Alimentary Pharmacology & Therapeutics.2025;[Epub]     CrossRef
  • Pharmacovigilance analysis of metabolic and nutritional adverse reactions associated with entecavir and tenofovir using the FDA adverse event reporting system database
    Haomin Zhu, Baolong Ding, Zhuying Jing, Hongting Yao, Yue Li, Lihong Gao, Yulu Zhu, Xin Li
    International Journal of Clinical Pharmacy.2025; 47(5): 1510.     CrossRef
  • Antiviral Therapy Reduces Dyslipidemia and Cardiovascular Risk in Chronic Hepatitis B: TDF as the Most Effective Agent
    Hyuk Kim, Jae‐Young Kim, Hyun Bin Choi, Ji‐Soo Lee, Yoon E. Shin, Jeong‐Ju Yoo, Sang Gyune Kim, Young‐Seok Kim
    Journal of Medical Virology.2025;[Epub]     CrossRef
  • Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients Treated With Tenofovir Alafenamide or Tenofovir Disoproxil Fumarate
    Jiwon Yang, Jihye Lim, Ye‐Jee Kim, Hwa Jung Kim, Jonggi Choi
    Liver International.2025;[Epub]     CrossRef
  • Letter: Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide fumarate in patients with chronic hepatitis B: More questions than an answer – author’s reply
    Hyeyeon Hong, Jonggi Choi
    Clinical and Molecular Hepatology.2024; 30(2): 272.     CrossRef
  • Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide in patients with chronic hepatitis B: More questions than an answer
    Pin-Nan Cheng, Ming-Lung Yu
    Clinical and Molecular Hepatology.2024; 30(2): 144.     CrossRef
  • Lipid safety of tenofovir alafenamide during 96-week treatment in treatment-naive chronic hepatitis B patients
    Wenjuan Zhao, Yi Liu, Mengdi Zhang, Zixin Cui, Zhan Qu, Yiyang Li, Meijuan Wan, Wen Wang, Yunru Chen, Lei Shi, Jianzhou Li, Feng Ye
    Frontiers in Medicine.2024;[Epub]     CrossRef
  • Reply to correspondence on “Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide”
    Pin-Nan Cheng, Ming-Lung Yu
    Clinical and Molecular Hepatology.2024; 30(4): 1031.     CrossRef
  • Effects of tenofovir alafenamide fumarate on serum lipid profiles in patients with chronic hepatitis B
    Fei Cao, Tao Fan, Xue Jiang, Jian Wang, Yilin Liu, Li Zhu, Ye Xiong, Shaoqiu Zhang, Zhiyi Zhang, Yifan Pan, Yuanyuan Li, Chao Jiang, Juan Xia, Xiaomin Yan, Jie Li, Xingxiang Liu, Chuanwu Zhu, Rui Huang, Chao Wu
    Virology Journal.2024;[Epub]     CrossRef
  • Eight‐year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: Final results from two randomised phase 3 trials
    Maria Buti, Young‐Suk Lim, Henry Lik Yuen Chan, Kosh Agarwal, Patrick Marcellin, Maurizia R. Brunetto, Wan‐Long Chuang, Harry L. A. Janssen, Scott K. Fung, Namiki Izumi, Maciej S. Jablkowski, Dzhamal Abdurakhmanov, Frida Abramov, Hongyuan Wang, Irina Botr
    Alimentary Pharmacology & Therapeutics.2024; 60(11-12): 1573.     CrossRef
  • 6,664 View
  • 277 Download
  • 21 Web of Science
  • Crossref

Hepatic neoplasm

Loco-regional therapies competing with radiofrequency ablation in potential indications for hepatocellular carcinoma: a network meta-analysis
Ha Il Kim, Jihyun An, Seungbong Han, Ju Hyun Shim
Clin Mol Hepatol 2023;29(4):1013-1028.
Published online July 5, 2023
DOI: https://doi.org/10.3350/cmh.2023.0131
Background/Aims
There is no clear consensus on the relative ranking of interventional and radiation techniques with indications similar to those of radiofrequency ablation (RFA) for the treatment of early hepatocellular carcinoma (HCC). We used a network meta-analysis to compare the efficacy of non-surgical treatments for early HCC.
Methods
We searched databases for randomized trials assessing the efficacy of loco-regional treatments for HCCs ≤5 cm with no extrahepatic spread or portal invasion. The primary outcome was the pooled hazard ratio (HR) for overall survival (OS), and secondary outcomes included overall and local progression-free survival (PFS). A frequentist network meta-analysis was performed, and the relative ranking of therapies was assessed with P-scores.
Results
Nineteen studies comparing 11 different strategies in 2,793 patients were included. Chemoembolization plus RFA improved OS better than RFA alone (HR 0.52, 95% confidence interval [CI] 0.33–0.82; P-score=0.951). Cryoablation, microwave ablation, laser ablation, and proton beam therapy had similar effects on OS compared with RFA. For overall PFS, but not local PFS, only chemoembolization plus RFA performed significantly better than RFA (HR 0.61, 95% CI 0.42–0.88; P-score=0.964). Injection of percutaneous ethanol or acetic acid was significantly less effective than RFA for all measured outcomes, while no differences in progression outcomes were identified for other therapies included in the network.
Conclusions
Our results suggest that chemoembolization combined with RFA is the best option for local treatment of early HCC. Cases with potential contraindications for RFA may benefit from a tailored approach using thermal or radiation modalities.

Citations

Citations to this article as recorded by  Crossref logo
  • A network meta-analysis of different interventional treatment strategies for unresectable hepatocellular carcinoma
    Xing-Yan Le, Jun-Bang Feng, Xiao-Li Yu, Sui-Li Li, Xiaocai Zhang, Jiaqing Li, Chuan-Ming Li
    BMC Gastroenterology.2025;[Epub]     CrossRef
  • Association between early job loss and prognosis among hepatocellular carcinoma survivors
    B Yun, J Oh, S H Ahn, B K Kim, J-H Yoon
    Occupational Medicine.2025; 75(2): 113.     CrossRef
  • The Emerging Landscape for Combating Resistance Associated with Energy‐Based Therapies via Nanomedicine
    Qitao Hu, Huali Zuo, Jessica C. Hsu, Cheng Zeng, Zhou Tian, Zhouyi Sun, Weibo Cai, Zhe Tang, Weiyu Chen
    Advanced Materials.2024;[Epub]     CrossRef
  • Efficacy and Safety of CT-guided Percutaneous Cryoablation for Hepatocellular Carcinoma at High-risk Sites
    Weihao Zhang, Yan Wang, Xiaohui Zhao, Wei Gao, Changfu Liu, Tongguo Si, Xueling Yang, Wenge Xing, Haipeng Yu
    Academic Radiology.2024; 31(11): 4434.     CrossRef
  • Chemoembolization combined with radiofrequency ablation is the best option for the local treatment of early hepatocellular carcinoma?
    Hyo-Cheol Kim
    Clinical and Molecular Hepatology.2023; 29(4): 984.     CrossRef
  • 8,056 View
  • 180 Download
  • 5 Web of Science
  • Crossref

Letter to the Editor

Liver fibrosis, cirrhosis, and portal hypertension

  • 5,237 View
  • 67 Download

Original Articles

Liver fibrosis, cirrhosis, and portal hypertension

Cervicocerebral atherosclerosis and its hepatic and coronary risk factors in patients with liver cirrhosis
Jihyun An, Hyung-Don Kim, Seon-Ok Kim, Ha Il Kim, Gi-Won Song, Han Chu Lee, Ju Hyun Shim
Clin Mol Hepatol 2022;28(1):67-76.
Published online October 12, 2021
DOI: https://doi.org/10.3350/cmh.2021.0202
Background/Aims
We aimed to investigate the silent atherosclerotic burden of cervicocephalic vessels in cirrhotic patients compared with the general population, as well as the relevant risk factors including coronary parameters.
Methods
This study included 993 stroke-free patients with liver cirrhosis (LC) who underwent magnetic resonance angiography (MRA) of the head and neck as a pre-liver transplant assessment and 6,099 health checkup participants who underwent MRA examination. The two cohorts were matched for cerebrovascular risk factors, and the prevalence of atherosclerosis in major intracranial and extracranial arteries was compared in 755 matched pairs. Moreover, traditional, hepatic, and coronary variables related to cerebral atherosclerosis were assessed in cirrhotic patients.
Results
Overall, intracranial atherosclerosis was significantly less prevalent in the LC group than in the matched control group (2.3% vs. 5.4%, P=0.002), whereas the prevalence of extracranial atherosclerosis was similar (4.4% vs. 5.8%, P=0.242). These results were maintained in multivariate analyses of the pooled samples, with corresponding adjusted odds ratios [ORs] of LC of 0.56 and 0.77 (95% confidence intervals [CIs], 0.36–0.88 and 0.55–1.09). In the LC group, lower platelet count was inversely correlated with intracranial atherosclerosis (adjusted OR, 0.31; 95% CI, 0.13–0.76). Coronary artery calcium (CAC) score ≥100 was the only predictive factor for both intracranial and extracranial atherosclerosis (adjusted ORs, 4.06 and 5.43, respectively).
Conclusions
LC confers protection against intracranial atherosclerosis, and thrombocytopenia may be involved in this protective effect. High CAC score could serve as a potential surrogate for cervicocerebral vascular screening in asymptomatic cirrhotic patients.

Citations

Citations to this article as recorded by  Crossref logo
  • Letter: cervicocerebral atherosclerosis and its hepatic and coronary risk factors in patients with liver cirrhosis
    Yi-Chun Huang, Chih-Wei Chen, James Chun-Chung Wei
    Clinical and Molecular Hepatology.2022; 28(2): 265.     CrossRef
  • Reply: Letter: cervicocerebral atherosclerosis and its hepatic and coronary risk factors in patients with liver cirrhosis
    Jihyun An, Ju Hyun Shim
    Clinical and Molecular Hepatology.2022; 28(2): 267.     CrossRef
  • 7,968 View
  • 186 Download
  • 2 Web of Science
  • Crossref

Hepatic neoplasm

Stereotactic body radiation therapy for small (≤5 cm) hepatocellular carcinoma not amenable to curative treatment: Results of a single-arm, phase II clinical trial
Sang Min Yoon, So Yeon Kim, Young-Suk Lim, Kang Mo Kim, Ju Hyun Shim, Danbi Lee, Jihyun An, Jinhong Jung, Jong Hoon Kim, Han Chu Lee
Clin Mol Hepatol 2020;26(4):506-515.
Published online July 10, 2020
DOI: https://doi.org/10.3350/cmh.2020.0038
Background/Aims
Stereotactic body radiation therapy (SBRT) is used as an alternative ablative treatment in patients with hepatocellular carcinoma (HCC) not suitable for curative treatments. The purpose of this prospective study was to evaluate the long-term efficacy of SBRT for small (≤5 cm) HCCs.
Methods
A phase II, single-arm clinical trial on SBRT for small HCCs was conducted at an academic tertiary care center. The planned SBRT dose was 45 Gy with a fraction size of 15-Gy over 3 consecutive days. The primary endpoint was 2-year local control rate. Radiologic responses were assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1) and the modified RECIST criteria.
Results
Between 2013 and 2016, 50 patients (53 lesions) were enrolled, with a median follow-up period of 47.8 months (range, 2.9–70.6). Patients’ age ranged from 41 to 74 years, and 80% were male. Median tumor size was 1.3 cm (range, 0.7–3.1). The 2- and 5-year local control rates were 100% and 97.1%, respectively. The 5-year overall survival rate was 77.6%. Six months after SBRT, radiologic responses were evident in 44 lesions (83%) according to the RECIST criteria and 49 (92.4%) according to the modified RECIST criteria. None of the patients showed grade ≥3 adverse events.
Conclusions
SBRT showed excellent results as an ablative treatment for patients with small HCCs while showing minimal toxicities. SBRT can be a good alternative for both curative and salvage intents in patients with HCCs that are unsuitable for curative treatments.

Citations

Citations to this article as recorded by  Crossref logo
  • Exploring the Evolving Landscape of Stereotactic Body Radiation Therapy in Hepatocellular Carcinoma
    Deepti Sharma, Divya Khosla, Babu L. Meena, Hanuman P. Yadav, Rakesh Kapoor
    Journal of Clinical and Experimental Hepatology.2025; 15(1): 102386.     CrossRef
  • Stereotactic body radiotherapy alone versus stereotactic body radiotherapy after incomplete transarterial therapy for hepatocellular carcinoma
    Youngju Song, Jinhong Jung, Jin‐hong Park, So Yeon Kim, Jonggi Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young‐Suk Lim, Han Chu Lee, Sang Min Yoon
    Journal of Medical Imaging and Radiation Oncology.2025; 69(1): 144.     CrossRef
  • Comparison of stereotactic body radiotherapy and transcatheter arterial chemoembolization for hepatocellular carcinoma: Systematic review and meta‐analysis
    Satoshi Komiyama, Atsuya Takeda, Yudai Tateishi, Yuichiro Tsurugai, Takahisa Eriguchi, Nobuyuki Horita
    Radiotherapy and Oncology.2025; 202: 110614.     CrossRef
  • Development and Validation of a Prediction Model for Cardiac Events in Patients With Hepatocellular Carcinoma Undergoing Stereotactic Body Radiation Therapy
    Hye In Lee, Jaeman Son, Byungchul Cho, Youngmoon Goh, Jinhong Jung, Jin-hong Park, Eui Kyu Chie, Kyung Su Kim, Young-Hak Kim, Hyun-Cheol Kang, Sang Min Yoon
    International Journal of Radiation Oncology*Biology*Physics.2025; 122(5): 1272.     CrossRef
  • Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment
    Soo Young Hwang, Pojsakorn Danpanichkul, Vatche Agopian, Neil Mehta, Neehar D. Parikh, Ghassan K. Abou-Alfa, Amit G. Singal, Ju Dong Yang
    Clinical and Molecular Hepatology.2025; 31(Suppl): S228.     CrossRef
  • Proton beam therapy in the management of hepatocellular carcinoma
    Kenneth S. H. Chok, Tiffany Y. T. Joeng, Darren M. C. Poon
    Expert Review of Gastroenterology & Hepatology.2025; 19(5): 495.     CrossRef
  • Modern approach to hepatocellular carcinoma treatment
    Francesco Cortese, Fotis Anagnostopoulos, Maria Vittoria Bazzocchi, Silvio Caringi, Antonio Rosario Pisani, Matteo Renzulli, Ioannis Paraskevopoulos, Letizia Laera, Alessia Surgo, Stavros Spiliopoulos, Riccardo Memeo, Riccardo Inchingolo
    World Journal of Hepatology.2025;[Epub]     CrossRef
  • Dynamic Tumor Tracking (DTT) for Hepatocellular Carcinoma Using the Vero4DRT Gimbaled Linac Stereotactic Body Radiation Therapy (SBRT) System
    Ronan L. McDermott, Emma M. Dunne, Lok In Josephine Ma, Alanah M Bergman, Marie-Laure A. Camborde, Tania Karan, Ante Mestrovic, Emilie E. Carpentier, Mitchell C. C. Liu, Devin Schellenberg, Roy M. K. Ma
    Cancers.2025; 17(17): 2926.     CrossRef
  • Stereotactic hepatic radiation therapy and immunotherapy in hepatocellular carcinoma
    Carmen Cañadillas Navero, Íñigo San Miguel Arregui, Luis Alberto Pérez Romasanta
    Revisiones en Cáncer.2025;[Epub]     CrossRef
  • China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition)
    Jian Zhou, Huichuan Sun, Zheng Wang, Wenming Cong, Mengsu Zeng, Weiping Zhou, Lianxin Liu, Tianfu Wen, Ming Kuang, Bixiang Zhang, Kaishan Tao, Guohong Han, Zhiping Yan, Maoqiang Wang, Ruibao Liu, Jinhe Guo, Zhaochong Zeng, Ping Liang, Zhenggang Ren, Jinli
    Liver Cancer.2025; : 1.     CrossRef
  • Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Meta-Analysis and International Stereotactic Radiosurgery Society Practice Guidelines
    Sun Hyun Bae, Seok-Joo Chun, Joo-Hyun Chung, Eunji Kim, Jin-Kyu Kang, Won Il Jang, Ji Eun Moon, Isaure Roquette, Xavier Mirabel, Tomoki Kimura, Masayuki Ueno, Ting-Shi Su, Alison C. Tree, Matthias Guckenberger, Simon S. Lo, Marta Scorsetti, Ben J. Slotman
    International Journal of Radiation Oncology*Biology*Physics.2024; 118(2): 337.     CrossRef
  • Concurrent nivolumab and external beam radiation therapy for hepatocellular carcinoma with macrovascular invasion: A phase II study
    Bo Hyun Kim, Hee Chul Park, Tae Hyun Kim, Young-Hwan Koh, Jung Yong Hong, Yuri Cho, Dong Hyun Sinn, Boram Park, Joong-Won Park
    JHEP Reports.2024; 6(4): 100991.     CrossRef
  • Chemoembolization versus Radiotherapy for Single Hepatocellular Carcinomas of ≤3 cm Unsuitable for Image-Guided Tumor Ablation
    Jihye Lim, Euichang Kim, Sehee Kim, So Yeon Kim, Jin Hyoung Kim, Sang Min Yoon, Ju Hyun Shim
    Gut and Liver.2024; 18(1): 125.     CrossRef
  • Canine primary liver tumors treated with stereotactic body radiation therapy: A case series
    Qiao Ying Pauline Chan, Deanna Morrow, David Lurie
    Veterinary Radiology & Ultrasound.2024; 65(2): 121.     CrossRef
  • Optimal hypofractionated radiation therapy schemes for early-stage hepatocellular carcinoma
    Feng Liu, Doris R. Brown, Michael T. Munley
    Radiotherapy and Oncology.2024; 194: 110223.     CrossRef
  • Stereotactic body radiation therapy in patients with centrally located hepatocellular carcinoma: A retrospective, single-arm, multi-center study
    Dan-Xue Zheng, Yi-Xing Chen, Jing Sun, Yong Hu, Ping Yang, Yang Zhang, Xue-Zhang Duan, Zhao-Chong Zeng
    Clinical and Translational Radiation Oncology.2024; 46: 100767.     CrossRef
  • Dynamic liver volume change in predicting hepatic decompensation and long‐term effects of stereotactic body radiation therapy
    Sumin Lee, Jonggi Choi, Jin‐hong Park, Chae Yeon Lim, Eunyeong Yang, Sang Min Yoon, Jinhong Jung
    Journal of Gastroenterology and Hepatology.2024; 39(8): 1648.     CrossRef
  • Stereotactic body radiotherapy is an alternative to radiofrequency ablation for single HCC ≤5.0 cm
    Zhoutian Yang, Shiliang Liu, Li Hu, Jinbin Chen, Juncheng Wang, Yangxun Pan, Li Xu, Mengzhong Liu, Minshan Chen, Mian Xi, Yaojun Zhang
    JHEP Reports.2024; 6(10): 101151.     CrossRef
  • Clinical outcomes and safety of external beam radiotherapy with extensive intrahepatic targets for advanced hepatocellular carcinoma: A single institutional clinical experience
    Sunmin Park, Chai Hong Rim, Won Sup Yoon
    Saudi Journal of Gastroenterology.2024; 30(6): 399.     CrossRef
  • Long-term outcomes of more than a decade treating patients with stereotactic body radiation therapy for hepatocellular carcinoma
    Wilhelm den Toom, Eva M. Negenman, Francois E.J.A. Willemssen, Erik van Werkhoven, Robert J. Porte, Roeland F. de Wilde, Dave Sprengers, Imogeen E. Antonisse, Ben J.M. Heijmen, Alejandra Méndez Romero
    Clinical and Translational Radiation Oncology.2024; 49: 100878.     CrossRef
  • Long-Term Outcome of a Multicenter Prospective Study on Efficacy and Safety of High-Dose Stereotactic Body Radiation Therapy ≥48-h Interfraction Interval for ≤5 cm Hepatocellular Carcinoma
    Jin-Kyu Kang, Mi-Sook Kim, Won Il Jang, Chul Ju Han, Jin Kim, Su Cheol Park, Young-Joo Shin, Chul Won Choi, Wan Jeon, Tosol Yu, Ah Ram Chang, Hae Jin Park, Younghee Park, Eun Seog Kim, Sunmi Jo, Woo Chul Kim, Hun Jung Kim, Sun Hyun Bae, Eunji Kim
    Liver Cancer.2024; 14(3): 248.     CrossRef
  • Advances in external beam radiation for hepatocellular carcinoma, stereotactic body radiation therapy (SBRT) and particle therapy
    Lokesh Seth, Kevin L. Stephans
    Hepatoma Research.2024;[Epub]     CrossRef
  • Therapeutic Outcome of Stereotactic Body Radiotherapy for Small Hepatocellular Carcinoma Lesions – A Systematic Review and Network Meta-analysis
    L.-Q. Li, T.-S. Su, Q.-Y. Wu, Z.-T. Lin, S.-X. Liang
    Clinical Oncology.2023; 35(10): 652.     CrossRef
  • Post-operative recurrence of liver cancer according to antiviral therapy for detectable hepatitis B viremia: A nationwide study
    Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin-Ha Yoon, Beom Kyung Kim
    European Journal of Internal Medicine.2023; 107: 66.     CrossRef
  • Stereotactic Body Radiotherapy for Hepatocellular Carcinoma: A Brief Overview
    Yukinori Matsuo
    Current Oncology.2023; 30(2): 2493.     CrossRef
  • Advances in Radiation Therapy for Primary Liver Cancer
    Kyle C. Cuneo, Daniel J. Herr
    Surgical Oncology Clinics of North America.2023; 32(3): 415.     CrossRef
  • 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

    Journal of Liver Cancer.2023; 23(1): 1.     CrossRef
  • Outcome of untreated low-level viremia versus antiviral therapy-induced or spontaneous undetectable HBV-DNA in compensated cirrhosis
    Daniel Q. Huang, Nobuharu Tamaki, Hyung Woong Lee, Soo Young Park, Yu Rim Lee, Hye Won Lee, Seng Gee Lim, Tae Seop Lim, Masayuki Kurosaki, Hiroyuki Marusawa, Toshie Mashiba, Masahiko Kondo, Yasushi Uchida, Haruhiko Kobashi, Koichiro Furuta, Namiki Izumi,
    Hepatology.2023; 77(5): 1746.     CrossRef
  • Stereotactic Body Radiation Therapy versus Surgical Resection for Stage I/II Hepatocellular Carcinoma
    Emrullah Birgin, Svetlana Hetjens, Moses Tam, Camilo Correa-Gallego, Nuh N. Rahbari
    Cancers.2023; 15(8): 2330.     CrossRef
  • Clinical impact of carbon‐ion radiotherapy on hepatocellular carcinoma with Child‐Pugh B cirrhosis
    Yuichi Hiroshima, Masaru Wakatsuki, Takashi Kaneko, Hirokazu Makishima, Naomi Nagatake Okada, Shigeo Yasuda, Hitoshi Ishikawa, Hiroshi Tsuji
    Cancer Medicine.2023; 12(13): 14004.     CrossRef
  • Local Therapies for Hepatocellular Carcinoma and Role of MRI-Guided Adaptive Radiation Therapy
    Yirong Liu, Brian Chou, Amulya Yalamanchili, Sara N. Lim, Laura A. Dawson, Tarita O. Thomas
    Journal of Clinical Medicine.2023; 12(10): 3517.     CrossRef
  • Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity
    Hideki Iwamoto, Shigeo Shimose, Tomotake Shirono, Takashi Niizeki, Takumi Kawaguchi
    Clinical and Molecular Hepatology.2023; 29(3): 593.     CrossRef
  • Impact of radiation therapy and alpha-fetoprotein level on survival outcomes for patients with hepatocellular carcinoma: A population-based study
    Yahong Chen, Xueqing Yang, Xiawei Li
    Clinics and Research in Hepatology and Gastroenterology.2023; 47(8): 102196.     CrossRef
  • Loco-regional therapies competing with radiofrequency ablation in potential indications for hepatocellular carcinoma: a network meta-analysis
    Ha Il Kim, Jihyun An, Seungbong Han, Ju Hyun Shim
    Clinical and Molecular Hepatology.2023; 29(4): 1013.     CrossRef
  • Large hepatocellular carcinoma treated with sequential SBRT and immunotherapy with anti-VEGF (Vascular Endothelial Growth Factor) therapy
    Bardia Bidarmaghz, Marwan Idrees, Yoo Young Lee, Peter Hodgkinson
    BMJ Case Reports.2023; 16(12): e256931.     CrossRef
  • Episodic Detectable Viremia Does Not Affect Prognosis in Untreated Compensated Cirrhosis With Serum Hepatitis B Virus DNA <2,000 IU/mL
    Hye Won Lee, Soo Young Park, Yu Rim Lee, Hyein Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    American Journal of Gastroenterology.2022; 117(2): 288.     CrossRef
  • Stereotactic body radiation therapy for primary liver tumors: An effective liver‐directed therapy in the toolbox
    Hannah J. Roberts, Jennifer Y. Wo
    Cancer.2022; 128(5): 956.     CrossRef
  • External Validation of the FSAC Model Using On-Therapy Changes in Noninvasive Fibrosis Markers in Patients with Chronic Hepatitis B: A Multicenter Study
    Jae Seung Lee, Hyun Woong Lee, Tae Seop Lim, In Kyung Min, Hye Won Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Cancers.2022; 14(3): 711.     CrossRef
  • Stereotactic body radiation therapy as a salvage treatment for single viable hepatocellular carcinoma at the site of incomplete transarterial chemoembolization: a retrospective analysis of 302 patients
    Sumin Lee, Jinhong Jung, Jin-hong Park, So Yeon Kim, Jonggi Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Hee Hyun Park, Jong Hoon Kim, Sang Min Yoon
    BMC Cancer.2022;[Epub]     CrossRef
  • Hypofractionation in Hepatocellular Carcinoma – The Effect of Fractionation Size
    S. Lewis, A. Barry, M.A. Hawkins
    Clinical Oncology.2022; 34(5): e195.     CrossRef
  • Stereotactic body radiation therapy for hepatocellular carcinoma: From infancy to ongoing maturity
    Shirley Lewis, Laura Dawson, Aisling Barry, Teodor Stanescu, Issa Mohamad, Ali Hosni
    JHEP Reports.2022; 4(8): 100498.     CrossRef
  • The role of stereotactic body radiotherapy in hepatocellular carcinoma: guidelines and evidences
    Yulin Hu, Caining Zhao, Ren Ji, Wenqi Chen, Qi Shen, CL Chiang, Jeff Chan, Lingyu Ma, Hongwei Yang, Tiffany Wong, Susannah Ellsworth, Chung-Mau Lo, Laura A. Dawson, Feng-Ming (Spring) Kong
    Journal of the National Cancer Center.2022; 2(3): 171.     CrossRef
  • Prognosis and Risk Factors of Recurrence in HBV-Related Small Hepatocellular Carcinoma After Stereotactic Body Radiation Therapy
    Yifan Han, Jianxiang Liu, Jiali Pan, Hongyu Chen, Ning Tan, Qian Kang, Yuqing Yang, Xiaoyuan Xu, Wengang Li
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • High rates of treatment stage migration for early hepatocellular carcinoma and association with adverse outcomes: An Australian multicenter study
    Kee Fong Loo, Richard J Woodman, Damjana Bogatic, Vidyaleha Chandran, Kate Muller, Mohamed Asif Chinnaratha, John Bate, Kirsty Campbell, Matthew Maddison, Sumudu Narayana, Hien Le, David Pryor, Alan Wigg
    JGH Open.2022; 6(9): 599.     CrossRef
  • Stereotactic body radiotherapy versus radiofrequency ablation as initial treatment of small hepatocellular carcinoma
    Hwang Sik Shin, Sae Hwan Lee, Baek Gyu Jun, Hong Soo Kim, Seong Hee Kang, Ji Young Park, Soo In Choi, Gab Jin Cheon, Young Don Kim, Jeong-Ju Yoo, Sang Gyune Kim, Young Seok Kim, Soung Won Jeong, Jae Young Jang, Ki Tae Suk, Dong Joon Kim, In Young Jo, Yong
    European Journal of Gastroenterology & Hepatology.2022; 34(11): 1187.     CrossRef
  • 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

    Clinical and Molecular Hepatology.2022; 28(4): 583.     CrossRef
  • Prognostic Impact of MAFLD Following Surgical Resection of Hepatitis B Virus-Related Hepatocellular Carcinoma: A Nationwide Cohort Study
    Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin-Ha Yoon, Beom Kyung Kim
    Cancers.2022; 14(20): 5002.     CrossRef
  • Stereotactic body radiation therapy for elderly patients with small hepatocellular carcinoma: a retrospective observational study
    Jeong Yun Jang, Jinhong Jung, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Jin-hong Park, Sang Min Yoon
    Journal of Liver Cancer.2022; 22(2): 136.     CrossRef
  • 2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma

    Korean Journal of Radiology.2022; 23(12): 1126.     CrossRef
  • Image-Guided Proton Therapy for Elderly Patients with Hepatocellular Carcinoma: High Local Control and Quality of Life Preservation
    Hiromitsu Iwata, Hiroyuki Ogino, Yukiko Hattori, Koichiro Nakajima, Kento Nomura, Kensuke Hayashi, Toshiyuki Toshito, Shigeru Sasaki, Shingo Hashimoto, Jun-etsu Mizoe, Yuta Shibamoto
    Cancers.2021; 13(2): 219.     CrossRef
  • A New Prognostic Model for Radiation-Based Hepatocellular Carcinoma Treatment
    Ting-Shi Su, Shi-Xiong Liang, Li-Qing Li, Qiu-Hua Liu, Xue-Zhang Duan, Jing Sun, Hai Zeng, Jian-Xu Li, Xiao-Fei Zhu, Hong-Qing Zhuang, Ping Liang
    SSRN Electronic Journal .2021;[Epub]     CrossRef
  • Metformin and Dichloroacetate Suppress Proliferation of Liver Cancer Cells by Inhibiting mTOR Complex 1
    Tae Suk Kim, Minjong Lee, Minji Park, Sae Yun Kim, Min Suk Shim, Chea Yeon Lee, Dae Hee Choi, Yuri Cho
    International Journal of Molecular Sciences.2021; 22(18): 10027.     CrossRef
  • External validation of CAGE‐B and SAGE‐B scores for Asian chronic hepatitis B patients with well‐controlled viremia by antivirals
    Jung Hyun Ji, Soo Young Park, Won Jeong Son, Hye Jung Shin, Hyein Lee, Hye Won Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Journal of Viral Hepatitis.2021; 28(6): 951.     CrossRef
  • Radiofrequency ablation versus stereotactic body radiation therapy for small (≤ 3 cm) hepatocellular carcinoma: A retrospective comparison analysis
    Yuri Jeong, Kyung Jin Lee, So Jung Lee, Yong Moon Shin, Min‐Ju Kim, Young‐Suk Lim, Han Chu Lee, Jinhong Jung, Jin‐hong Park, Jong Hoon Kim, So Yeon Kim, Sang Min Yoon
    Journal of Gastroenterology and Hepatology.2021; 36(7): 1962.     CrossRef
  • Updates on the Diagnosis and Management of Hepatocellular Carcinoma
    Muhammad Kamran, Aimun Raees, Wasim Jafri
    Euroasian Journal of Hepato-Gastroenterology.2021; 11(1): 32.     CrossRef
  • Optimal stereotactic body radiotherapy dosage for hepatocellular carcinoma: a multicenter study
    Ting-Shi Su, Qiu-Hua Liu, Xiao-Fei Zhu, Ping Liang, Shi-Xiong Liang, Lin Lai, Ying Zhou, Yong Huang, Tao Cheng, Le-Qun Li
    Radiation Oncology.2021;[Epub]     CrossRef
  • Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B
    Hye Won Lee, Young Youn Cho, Hyein Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim, Soo Young Park
    Journal of Viral Hepatitis.2021; 28(11): 1570.     CrossRef
  • Multi-Institutional Retrospective Study of Radiotherapy for Hepatocellular Carcinoma in the Caudate Lobe
    Sung Uk Lee, Sang Min Yoon, Jason Chia-Hsien Cheng, Tae Hyun Kim, Bo Hyun Kim, Jin-hong Park, Jinhong Jung, Chiao-Ling Tsai, Yun Chiang, Joong-Won Park
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma
    Sojung Han, Hye Jin Choi, Seung-Hoon Beom, Hye Rim Kim, Hyein Lee, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jinsil Seong, Jong Yun Won, Beom Kyung Kim
    Journal of Cancer Research and Clinical Oncology.2021; 147(10): 3123.     CrossRef
  • The Prognostic Role of On-Treatment Liver Stiffness for Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B
    Hye Won Lee, Hyun Woong Lee, Jae Seung Lee, Yun Ho Roh, Hyein Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Journal of Hepatocellular Carcinoma.2021; Volume 8: 467.     CrossRef
  • Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B
    Hye Won Lee, Young Youn Cho, Hyein Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim, Soo Young Park
    Hepatology International.2021; 15(5): 1083.     CrossRef
  • Stereotactic body radiotherapy vs radiofrequency ablation for the treatment of hepatocellular carcinoma: a meta-analysis
    Antonio Facciorusso, Andrea Chierici, Ivan Cincione, Rodolfo Sacco, Daryl Ramai, Babu P Mohan, Saurabh Chandan, Andrew Ofosu, Christian Cotsoglou
    Expert Review of Anticancer Therapy.2021; 21(6): 681.     CrossRef
  • Novel Liver Stiffness-Based Nomogram for Predicting Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis B Virus Infection Initiating Antiviral Therapy
    Jae Seung Lee, Hyun Woong Lee, Tae Seop Lim, Hye Jung Shin, Hye Won Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Cancers.2021; 13(23): 5892.     CrossRef
  • In reply to Huo et al.: Treating small hepatocellular carcinoma: Stereotactic body radiation therapy versus radiofrequency ablation
    S Park, J Jung, B Cho, SY Kim, S‐C Yun, Y‐S Lim, HC Lee, J Park, J‐h Park, JH Kim, SM Yoon
    Journal of Gastroenterology and Hepatology.2020; 35(12): 2293.     CrossRef
  • 10,868 View
  • 226 Download
  • 62 Web of Science
  • Crossref

Editorial

Hepatic neoplasm

Citations

Citations to this article as recorded by  Crossref logo
  • The emerging age-pattern changes of patients with hepatocellular carcinoma in Korea
    Yuri Cho, Bo Hyun Kim, Joong-Won Park
    Clinical and Molecular Hepatology.2023; 29(1): 99.     CrossRef
  • Impact of metabolic risk factors on hepatic and cardiac outcomes in patients with alcohol- and non-alcohol-related fatty liver disease
    Jihye Lim, Hyunji Sang, Ha Il Kim
    JHEP Reports.2023; 5(6): 100721.     CrossRef
  • Surveillance for hepatocellular carcinoma: It is time to move forward
    Bo Hyun Kim, Yuri Cho, Joong-Won Park
    Clinical and Molecular Hepatology.2022; 28(4): 810.     CrossRef
  • Metformin and Dichloroacetate Suppress Proliferation of Liver Cancer Cells by Inhibiting mTOR Complex 1
    Tae Suk Kim, Minjong Lee, Minji Park, Sae Yun Kim, Min Suk Shim, Chea Yeon Lee, Dae Hee Choi, Yuri Cho
    International Journal of Molecular Sciences.2021; 22(18): 10027.     CrossRef
  • Surveillance of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease
    Yoshio Sumida, Masashi Yoneda, Yuya Seko, Hiroshi Ishiba, Tasuku Hara, Hidenori Toyoda, Satoshi Yasuda, Takashi Kumada, Hideki Hayashi, Takashi Kobayashi, Kento Imajo, Masato Yoneda, Toshifumi Tada, Takumi Kawaguchi, Yuichiro Eguchi, Satoshi Oeda, Hirokaz
    Diagnostics.2020; 10(8): 579.     CrossRef
  • Serum Myostatin Predicts the Risk of Hepatocellular Carcinoma in Patients with Alcoholic Cirrhosis: A Multicenter Study
    Ji Hyun Kim, Seong Hee Kang, Minjong Lee, Gi Soo Youn, Tae Suk Kim, Baek Gyu Jun, Moon Young Kim, Young Don Kim, Gab Jin Cheon, Dong Joon Kim, Soon Koo Baik, Dae Hee Choi, Ki Tae Suk
    Cancers.2020; 12(11): 3347.     CrossRef
  • 6,798 View
  • 120 Download
  • 6 Web of Science
  • Crossref

Original Articles

Hepatic neoplasm

Comparison of surgical resection versus transarterial chemoembolization with additional radiation therapy in patients with hepatocellular carcinoma with portal vein invasion
Danbi Lee, Han Chu Lee, Jihyun An, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Young-Hwa Chung, Yung Sang Lee
Clin Mol Hepatol 2018;24(2):144-150.
Published online January 16, 2018
DOI: https://doi.org/10.3350/cmh.2017.0041
Background/Aims
Portal vein invasion (PVI) is a poor prognostic factor in patients with hepatocellular carcinoma (HCC). We intended to compare the effects of surgical resection and transarterial chemoembolization (TACE) with additional radiation therapy (RT) in HCC patients with PVI.
Methods
The subjects comprised 43 patients who underwent surgical resection for HCC with PVI without previous treatment and another 43 patients who received TACE followed by RT (TACE+RT) as initial treatment who were matched for Child-Pugh class, tumor size, and extent of PVI. Disease progression and death after the treatment were examined, and progression-free survival (PFS) and overall survival (OS) were compared between groups. Predisposing factors affecting OS were analyzed using univariate and multivariate analyses in HCC patients with PVI.
Results
The subjects (Age [51, 24-74; median, range], Sex [81/13; male/female], Etiology [78/1/15; hepatitis B virus {HBV}/ hepatitis C virus {HCV}/non-HBV and non-HCV]) were followed for a median of 17 (2-68) months. There were no differences in clinical or tumor characteristics between the resection and TACE+RT groups. The cumulative PFS was not significantly different between groups. The median PFS was 5.6 and 4.0 months in the resection and TACE+RT groups, respectively. However, the cumulative OS was significantly longer in patients treated with resection than in those treated with TACE+RT (P=0.04). The median OS was 26.9 and 14.2 months in the resection and TACE+RT groups, respectively. Univariate and multivariate analyses revealed that surgical resection was an independent predictive factor for better survival outcome.
Conclusions
Surgical resection might be an effective treatment in HCC patients with PVI.

Citations

Citations to this article as recorded by  Crossref logo
  • Subclassification of advanced-stage hepatocellular carcinoma with macrovascular invasion: combined transarterial chemoembolization and radiotherapy as an alternative first-line treatment
    Sujin Jin, Won-Mook Choi, Ju Hyun Shim, Danbi Lee, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Jinhong Jung, Sang Min Yoon, Jonggi Choi
    Journal of Liver Cancer.2023; 23(1): 177.     CrossRef
  • Efficacy and feasibility of surgery and external radiotherapy for hepatocellular carcinoma with portal invasion: A meta-analysis
    Han Ah Lee, Yeon Seok Seo, In-Soo Shin, Won Sup Yoon, Hye Yoon Lee, Chai Hong Rim
    International Journal of Surgery.2022; 104: 106753.     CrossRef
  • Direct-Acting Antivirals Improve Treatment Outcomes in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma Treated with Transarterial Chemoembolization: A Nationwide, Multi-center, Retrospective Cohort Study
    Hye Kyung Hyun, Eun Ju Cho, Soo Young Park, Young Mi Hong, Soon Sun Kim, Hwi Young Kim, Nae-Yun Heo, Jung Gil Park, Dong Hyun Sinn, Wonseok Kang, Song Won Jeong, Myeong Jun Song, Hana Park, Danbi Lee, Yong Sun Lee, Sung Bum Cho, Chan Sik An, Hyung Jin Rhe
    Digestive Diseases and Sciences.2021; 66(7): 2427.     CrossRef
  • Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma
    Soojin Kim, Kyung Hyun Kim, Beom Kyung Kim, Jun Yong Park, Sang Hoon Ahn, Do Young Kim, Seung Up Kim
    Journal of Gastroenterology and Hepatology.2021; 36(5): 1317.     CrossRef
  • Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma
    Sojung Han, Hye Jin Choi, Seung-Hoon Beom, Hye Rim Kim, Hyein Lee, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jinsil Seong, Jong Yun Won, Beom Kyung Kim
    Journal of Cancer Research and Clinical Oncology.2021; 147(10): 3123.     CrossRef
  • Validation of Pre-/Post-TACE-Predict Models among Patients with Hepatocellular Carcinoma Receiving Transarterial Chemoembolization
    David Sooik Kim, Beom Kyung Kim, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim
    Cancers.2021; 14(1): 67.     CrossRef
  • Prognosis of Early-Stage Hepatocellular Carcinoma: Comparison between Trans-Arterial Chemoembolization and Radiofrequency Ablation
    Byung-Yoon Yun, Hye Won Lee, In Kyung Min, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Cancers.2020; 12(9): 2527.     CrossRef
  • Appraisal of Long-Term Outcomes of Liver-Directed Concurrent Chemoradiotherapy for Hepatocellular Carcinoma with Major Portal Vein Invasion


    Sojung Han, Hye Won Lee, Jun Yong Park, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jinsil Seong, Jong Yun Won, Dai Hoon Han, Beom Kyung Kim
    Journal of Hepatocellular Carcinoma.2020; Volume 7: 403.     CrossRef
  • Prognostic assessment using a new substaging system for Barcelona clinic liver cancer stage C hepatocellular carcinoma: A nationwide study
    Dong‐won Lee, Hyung Joon Yim, Yeon Seok Seo, Seong Kyun Na, Seung Young Kim, Sang Jun Suh, Jong Jin Hyun, Sung Woo Jung, Young Kul Jung, Ja Seol Koo, Ji Hoon Kim, Jong Eun Yeon, Sang Woo Lee, Kwan Soo Byun, Soon Ho Um
    Liver International.2019; 39(6): 1109.     CrossRef
  • Evaluating the role of RAD52 and its interactors as novel potential molecular targets for hepatocellular carcinoma
    Ping Li, YanZhen Xu, Qinle Zhang, Yu Li, Wenxian Jia, Xiao Wang, Zhibin Xie, Jiayi Liu, Dong Zhao, Mengnan Shao, Suixia Chen, Nanfang Mo, Zhiwen Jiang, Liuyan Li, Run Liu, Wanying Huang, Li Chang, Siyu Chen, Hongtao Li, Wenpu Zuo, Jiaquan Li, Ruoheng Zhan
    Cancer Cell International.2019;[Epub]     CrossRef
  • Comparison of surgical resection versus transarterial chemoembolization with additional radiation therapy in patients with hepatocellular carcinoma with portal vein invasion
    Jin Wook Chung
    Clinical and Molecular Hepatology.2018; 24(2): 135.     CrossRef
  • 11,776 View
  • 181 Download
  • 12 Web of Science
  • Crossref

Hepatic neoplasm

Clinical features and outcomes of patients with hepatocellular carcinoma complicated with bile duct invasion
Jihyun An, Kwang Sun Lee, Kang Mo Kim, Do Hyun Park, Sang Soo Lee, Danbi Lee, Ju Hyun Shim, Young-Suk Lim, Han Chu Lee, Young-Hwa Chung, Yung Sang Lee
Clin Mol Hepatol 2017;23(2):160-169.
Published online May 16, 2017
DOI: https://doi.org/10.3350/cmh.2016.0088
Background/Aims
Little is known about the treatment or outcomes of hepatocellular carcinoma (HCC) complicated with bile duct invasion.
Methods
A total of 247 consecutive HCC patients with bile duct invasion at initial diagnosis were retrospectively included.
Results
The majority of patients had Barcelona Clinic Liver Cancer (BCLC) stage C HCC (66.8%). Portal vein tumor thrombosis was present in 166 (67.2%) patients. Median survival was 4.1 months. Various modalities of treatment were initially employed including surgical resection (10.9%), repeated transarterial chemoembolization (TACE) (42.5%), and conservative management (42.9%). Among the patients with obstructive jaundice (n=88), successful biliary drainage was associated with better overall survival rate. Among the patients with BCLC stage C, overall survival differed depending on the initial treatment for HCC; surgical resection, TACE, systemic chemotherapy, and conservative management showed overall survival rates of 11.5, 6.0 ,2.4, and 1.6 months, respectively. After adjusting for confounders, surgical resection and repeated TACE were significant prognostic factors for HCC patients with bile duct invasion (hazard ratios 0.47 and 0.39, Ps <0.001, respectively).
Conclusions
The survival of HCC patients with bile duct invasion at initial diagnosis is generally poor. However, aggressive treatments for HCC such as resection or biliary drainage may be beneficial therapeutic options for patients with preserved liver function.

Citations

Citations to this article as recorded by  Crossref logo
  • Prediction Model of Survival in Unresectable HCC with Central Bile Duct Invasion Receiving TACE After Biliary Drainage: TEMP Score
    Wenzhe Fan, Xinlin Zheng, Weihong Zhang, Bowen Zhu, Yanqin Wu, Miao Xue, Rong Tang, Zhen Huang, Liangliang Qiao, Mingjian Lu, Jian Wu, Yiyang Tang, Jinghua Chen, Shugui Huang, Mingjun Bai, Jiaping Li
    Journal of Hepatocellular Carcinoma.2025; Volume 12: 615.     CrossRef
  • PBK as a novel biomarker performed excellent diagnostic and prognostic value in HCC associated with immune infiltration and methylation
    Beibei Lv, Fenna Zhang, Xinyi Zhang, Ziyi Wang, Shuai Hao, Na Ye, Na He
    Journal of Molecular Histology.2025;[Epub]     CrossRef
  • Efficacy and safety of endoscopic ultrasound-guided hepaticogastrostomy for biliary drainage in hypervascular hepatocellular carcinoma: a retrospective study from Japan
    Kenneth Tachi, Kazuo Hara, Nozomi Okuno, Shin Haba, Takamichi Kuwahara, Toshitaka Fukui, Ahmed Mohammed Sadek, Hossam El-Din Shaaban Mahmoud Ibrahim, Minako Urata, Takashi Kondo, Yoshitaro Yamamoto
    Clinical Endoscopy.2025; 58(3): 448.     CrossRef
  • Liver transplantation for spalt-like transcription factor 4-positive dual-phenotype hepatocellular carcinoma with microscopic bile duct tumor thrombus: a case report
    Songming Ding, Xiangyan Liu, Zhuoyi Wang, Shanjie Dong, Qinfen Xie, Shusen Zheng, Qiyong Li
    Endoscopy.2025; 57(S 01): E804.     CrossRef
  • Hepatocellular carcinoma treated with radical resection after endoscopic diagnosis of the extent of bile duct invasion: A case report
    Yudai Sato, Tomoko Tadokoro, Hiroki Yamana, Hiraki Akai, Kei Takuma, Naoki Fujita, Mai Nakahara, Kyoko Oura, Koji Fujita, Joji Tani, Hideki Kamada, Asahiro Morishita, Hideki Kobara, Seiko Kagawa, Reiji Haba, Keiichi Okano, Tsutomu Masaki
    DEN Open.2024;[Epub]     CrossRef
  • Transarterial Therapy for Hepatocellular Carcinoma Invading the Bile Duct
    Shiro Miyayama
    Interventional Radiology.2024; 9(1): 1.     CrossRef
  • Outcomes of jaundice in advanced hepatocellular carcinoma – a sub-Saharan perspective
    PB Keshaw, M Bernon, M Emmamally, R Khan, UK Kotze, R Segobin, D Creamer, JEJ Krige, E Jonas, S Sobnach
    South African Journal of Surgery.2024; 62(2): 108.     CrossRef
  • CORRECTION OF BILIARY HYPERTENSION IN THE TREATMENT OF PATIENTS WITH MECHANICAL JAUNDICE
    V. V. Boyko, Р. M. Smachilo, А. V. Maloshtan, V. M. Likhman, V. Yu. Brovkin
    Kharkiv Surgical School.2024; (1): 29.     CrossRef
  • The Treatment of Hepatocellular Carcinoma with Major Vascular Invasion
    Tomoko Tadokoro, Joji Tani, Asahiro Morishita, Koji Fujita, Tsutomu Masaki, Hideki Kobara
    Cancers.2024; 16(14): 2534.     CrossRef
  • DEB‐TACE versus cTACE for unresectable HCC with B1‐type bile duct invasion after successful biliary drainage: A propensity score matching analysis
    Wenzhe Fan, Xinlin Zheng, Xiao Zhao, Bowen Zhu, Yanqin Wu, Miao Xue, Rong Tang, Zhen Huang, Liangliang Qiao, Mingjian Lu, Yiyang Tang, Jian Wu, Jiaping Li
    Cancer Medicine.2024;[Epub]     CrossRef
  • Effect of Biliary Drainage on the Prognosis of Patients with Hepatocellular Carcinoma and Bile Duct Invasion
    Keungmo Yang, Hyun Yang, Chang Wook Kim, Hee Chul Nam, Ji Hoon Kim, Ahlim Lee, U Im Chang, Jin Mo Yang, Hae Lim Lee, Jung Hyun Kwon, Soon Woo Nam, Soon Kyu Lee, Pil Soo Sung, Ji Won Han, Jeong Won Jang, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon, Hee Ye
    Gut and Liver.2024; 18(5): 877.     CrossRef
  • Clinical Significance of Biliary Invasion at Diagnosis in Barcelona Clinic Liver Cancer Stage B–C Hepatocellular Carcinoma: A Nationwide Cohort Analysis in South Korea
    Chai Hong Rim, Won Sup Yoon, Sunmin Park
    Oncology.2024; : 1.     CrossRef
  • Efficacy Analysis of PTCD + TACE vs PTCD + Apatinib in the Treatment of HCC with Obstructive Jaundice: A Retrospective Study
    Haohao Lu, Bin Liang, Xiangwen Xia, Chuansheng Zheng
    Anti-Cancer Agents in Medicinal Chemistry.2024; 24(17): 1241.     CrossRef
  • Effect of Biliary Tract Invasion with Obstructive Jaundice on the Prognosis of Patients With Unresectable Hepatocellular Carcinoma
    Weiwei Jiang, Xiaobo Fu, Guobao Wang, Han Qi, Zixiong Chen, Fei Gao
    Academic Radiology.2023; 30(3): 483.     CrossRef
  • Effect of percutaneous stenting strategy of unresectable malignant hilar biliary obstruction by three‐dimensional reconstruction volumetry
    Xiaobo Fu, Weiwei Jiang, Maoyuan Mu, Guobao Wang, Han Qi, Zixiong Chen, Mengxuan Zuo, Fei Gao
    Cancer Medicine.2023; 12(8): 9506.     CrossRef
  • Multimodality imaging approach in identifying invasive hepatocellular carcinoma
    Neel Shroff, Woongsoon Choi, Mohamed Elshikh, Brian Wong, Peeyush Bhargava
    Clinical Imaging.2023; 97: 34.     CrossRef
  • Prognosis value of microscopic bile duct invasion in hepatocellular carcinoma: A multicenter study
    Qizhen Huang, Kongying Lin, Zhipeng Lin, Hongbin Ji, Xiaoyu Zhou, Bin Wang, Yufeng Chen, Chuandong Sun, Shuguo Zheng, Jinhong Chen, Yifan Wang, Yanming Zhou, Weiping Zhou, Yongyi Zeng
    Cancer Medicine.2023; 12(22): 20821.     CrossRef
  • Prognostic value of baseline imaging and clinical features in patients with advanced hepatocellular carcinoma
    Osman Öcal, Michael Ingrisch, Muzaffer Reha Ümütlü, Bora Peynircioglu, Christian Loewe, Otto van Delden, Vincent Vandecaveye, Bernhard Gebauer, Christoph J. Zech, Christian Sengel, Irene Bargellini, Roberto Iezzi, Alberto Benito, Maciej Pech, Peter Malfer
    British Journal of Cancer.2022; 126(2): 211.     CrossRef
  • Postoperative adjuvant transarterial chemoembolization improves outcomes of hepatocellular carcinoma associated with bile duct tumor thrombus: a propensity score matching analysis
    Zhen-Hua Chen, Jin-Kai Feng, Ju-Xian Sun, Jia-Yi Wu, Wei-Xing Guo, Jie Shi, Yong-Gang Wei, Jian-Yin Zhou, Zhi-Bo Zhang, Mao-Lin Yan, Shu-Qun Cheng
    HPB.2022; 24(4): 547.     CrossRef
  • Hepatocellular Carcinoma with Hepatic Duct Tumor Thrombus
    Shih-Feng Huang, Cheng-Chung Tsai
    Indian Journal of Surgery.2022; 84(S2): 434.     CrossRef
  • Transarterial chemoembolization for hepatocellular carcinoma with vascular invasion
    Shiro Miyayama, Yasuaki Arai, Osamu Matsui
    The British Journal of Radiology.2022;[Epub]     CrossRef
  • Proton Beam Therapy in Managing Unresectable Hepatocellular Carcinoma with Bile Duct Invasion
    Ching-Hsin Lee, An-Hsin Chen, Sheng-Ping Hung, Cheng-En Hsieh, Jeng-Hwei Tseng, Po-Jui Chen, Jen-Yu Cheng, Joseph Tung-Chieh Chang, Kun-Ming Chan, Shi-Ming Lin, Chen-Chun Lin, Wei-Ting Chen, Wan-Yu Chen, Bing-Shen Huang
    Cancers.2022; 14(7): 1616.     CrossRef
  • Prediction of effective percutaneous transhepatic biliary drainage in patients with hepatocellular carcinoma: A multi-central retrospective study
    Haofan Wang, Yitao Mao, Chunning Zhang, Xiaojun Hu, Bin Chen, Luwen Mu, Shuyi Wang, Yifen Lin, Zhanwang Xiang, Mingsheng Huang
    Liver Research.2022; 6(4): 269.     CrossRef
  • Cholangioscopic biopsy sample detection of bile duct invasion by hepatocellular carcinoma: an underappreciated entity
    Teddy Sutardji Nagaria, Isaac Raijman, Mohamed O. Othman, Gary Lloyd Horn, John M. Vierling, Juhi Mahadik, Sadhna Dhingra
    iGIE.2022; 1(1): 62.     CrossRef
  • Effectiveness, safety, and factors associated with the clinical success of endoscopic biliary drainage for patients with hepatocellular carcinoma: a retrospective multicenter study
    Akihiro Matsumi, Hironari Kato, Toru Ueki, Etsuji Ishida, Masahiro Takatani, Masakuni Fujii, Masaki Wato, Tatsuya Toyokawa, Ryo Harada, Hirofumi Tsugeno, Minoru Matsubara, Hiroshi Matsushita, Hiroyuki Okada
    BMC Gastroenterology.2021;[Epub]     CrossRef
  • Hepatocellular carcinoma recurrence in the extrahepatic bile duct wall: A case report
    Taku Matsumoto, Toshihiko Yoshida, Takashi Yamagishi, Hironobu Goto, Dai Otsubo, Akinobu Furutani, Hisoka Yamane, Yasuhiro Fujino, Masahiro Tominaga
    Clinical Case Reports.2021; 9(3): 1561.     CrossRef
  • A nomogram based on combining systemic and hepatic inflammation markers for predicting microscopic bile duct tumour thrombus in hepatocellular carcinoma
    Jun-Yi Wu, Ju-Xian Sun, Jia-Yi Wu, Xiao-Xiao Huang, Yan-Nan Bai, Yong-Yi Zeng, Zhi-Bo Zhang, Shu-Qun Cheng, Mao-Lin Yan
    BMC Cancer.2021;[Epub]     CrossRef
  • Efficacy and Safety of Transarterial Chemoembolization for the Treatment of Unresectable Hepatocellular Carcinoma Associated with Bile Duct Tumor Thrombus: A Real-World Retrospective Cohort Study
    Jin-Kai Feng, Ju-Xian Sun, Zong-Han Liu, Jing-Wen Gu, Zhen-Hua Chen, Chang Liu, Wei-Xing Guo, Jie Shi, Shu-Qun Cheng
    Cancer Management and Research.2021; Volume 13: 3551.     CrossRef
  • Redefining Hepatocellular Carcinoma Staging Systems Based on the Bile Duct Invasion Status: A Multicenter Study
    Qizhen Huang, Yufeng Chen, Kongying Lin, Chuandong Sun, Shuguo Zheng, Jinhong Chen, Yifan Wang, Yanming Zhou, Weiping Zhou, Jingfeng Liu, Yongyi Zeng
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • The Model to Estimate Survival in Ambulatory Hepatocellular Carcinoma Patients Aids in the Decision for TACE Retreatment
    Young Youn Cho, Su Jong Yu, Jung-Ju Yoo, Minjong Lee, Dong Hyeon Lee, Yuri Cho, Kyoung Wan Yoon, Eun Ju Cho, Jeong-Hoon Lee, Yoon Jun Kim, Jung-Hwan Yoon
    Journal of Clinical Gastroenterology.2020; 54(4): 370.     CrossRef
  • Postoperative Adjuvant Transarterial Chemoembolization Improves Short-Term Prognosis of Hepatocellular Carcinoma with Bile Duct Tumor Thrombus: A Propensity-Score Matching Study


    Qizhen Huang, Kongying Lin, Lei Wang, Jianxing Zeng, Hongzhi Liu, Zongren Ding, Yongyi Zeng, Jingfeng Liu
    Cancer Management and Research.2020; Volume 12: 9183.     CrossRef
  • Glycochenodeoxycholic acid induces stemness and chemoresistance via the STAT3 signaling pathway in hepatocellular carcinoma cells
    Changying Shi, Jiamei Yang, Longmiao Hu, Boyi Liao, Liang Qiao, Weifeng Shen, Feng Xie, Guoqing Zhu
    Aging.2020; 12(15): 15546.     CrossRef
  • Triple Covered Metal Stent Deployment Using Side-by-Side Technique for Hemobilia due to Hepatocellular Carcinoma (with Video)
    Takeshi Ogura, Tadahiro Yamada, Masanori Yamada, Saori Ueno, Kazuhide Higuchi
    Digestive Diseases.2020; 38(4): 348.     CrossRef
  • Efficacy and Safety of Sorafenib in Unresectable Hepatocellular Carcinoma with Bile Duct Invasion
    Taku Tanaka, Teiji Kuzuya, Masatoshi Ishigami, Takanori Ito, Yoji Ishizu, Takashi Honda, Tetsuya Ishikawa, Mitsuhiro Fujishiro
    Oncology.2020; 98(9): 621.     CrossRef
  • FDG PET/CT Imaging of Hepatocellular Carcinoma With Bile Duct Tumor Thrombus
    Wei Zhang, Cheng Fang, Huipan Liu, Yue Chen
    Clinical Nuclear Medicine.2019; 44(2): 130.     CrossRef
  • Outcomes of major laparoscopic liver resection for hepatocellular carcinoma
    Hanisah Guro, Jai Young Cho, Ho-Seong Han, Yoo-Seok Yoon, YoungRok Choi, Sungho Kim, Kilhwan Kim, In Gun Hyun
    Surgical Oncology.2018; 27(1): 31.     CrossRef
  • Percutaneous placement of self-expandable metallic stents in patients with obstructive jaundice due to hepatocellular carcinoma
    Hyun Pyo Hong, Kyungmin Park
    International Journal of Gastrointestinal Intervention.2018; 7(2): 85.     CrossRef
  • 11,766 View
  • 251 Download
  • 44 Web of Science
  • Crossref

Liver Imaging

Vascular disorders of liver

Focal type of peliosis hepatis
Gil-Sun Hong, Kyoung Won Kim, Jihyun An, Ju Hyun Shim, Jihun Kim, Eun Sil Yu
Clin Mol Hepatol 2015;21(4):398-401.
Published online December 24, 2015
DOI: https://doi.org/10.3350/cmh.2015.21.4.398

Citations

Citations to this article as recorded by  Crossref logo
  • A unique presentation of peliosis hepatis: A case report and comprehensive review of the literature
    Alex Teshon, Crystal Walker, David P Schammel, Christine Marie-Gilligan Schammel, A Michael Devane
    International Journal of Hepatobiliary and Pancreatic Diseases.2023; 13(1): 16.     CrossRef
  • Histologic and microbiological findings of the defunctionalized loop in sleeve gastrectomy with jejunal bypass
    Matías Sepúlveda, Munir Alamo, Cristián Astorga, Yudith Preiss, Sebastián Saavedra
    Surgery for Obesity and Related Diseases.2021; 17(1): 131.     CrossRef
  • Hepatic disorders associated with exogenous sex steroids: MR imaging findings
    Cathryn L. Hui, Zhen Jiang Lee
    Abdominal Radiology.2019; 44(7): 2436.     CrossRef
  • Hepatic complications of oral contraceptive pills and estrogen on MRI: Controversies and update - Adenoma and beyond
    Janardhana Ponnatapura, Ania Kielar, Lauren M.B. Burke, Mark E. Lockhart, Abdul-Rahman Abualruz, Rafel Tappouni, Neeraj Lalwani
    Magnetic Resonance Imaging.2019; 60: 110.     CrossRef
  • Peliosis Hepatis Simulates Liver Metastases
    Bruna Migliavacca Zucchetti, Andrea Shimada, Luiz Tenorio Siqueira
    Journal of Global Oncology.2018; (4): 1.     CrossRef
  • A case of multiple spontaneous hepatic ruptures and literature review
    N. V. Tytarenko, O. V. Sergiychuk
    Perioperaciina Medicina.2018; 1(1): 60.     CrossRef
  • 11,557 View
  • 113 Download
  • 4 Web of Science
  • Crossref

Case Report

Benign liver tumors and cystic disease of liver

A case of primary hepatic actinomycosis: an enigmatic inflammatory lesion of the liver
Yeon Jung Ha, Ji Hyun An, Ju Hyun Shim, Eun Sil Yu, Jong Jae Kim, Tae Yong Ha, Han Chu Lee
Clin Mol Hepatol 2015;21(1):80-84.
Published online March 25, 2015
DOI: https://doi.org/10.3350/cmh.2015.21.1.80

Primary hepatic actinomycosis is one of the chronic abscess-forming infections of the liver. Accurate diagnosis is frequently delayed due to its indolent course and nonspecific clinical and radiological manifestations. We report a case of a 57-year-old man presenting with asymptomatic multiple hepatic masses on follow-up abdominal computed tomography performed 1 year after stomach cancer surgery. Although a percutaneous liver biopsy procedure was conducted twice in order to obtain confirmative pathology, only a nonspecific organizing abscess with plasma cell infiltration was revealed, without identification of any organism in the tissue cultures. Ultimately, actinomycosis was diagnosed following the detection of sulfur granules on open surgical biopsied tissue. This case suggests that primary hepatic actinomycosis should be considered as one of the possible causes for enigmatic inflammatory lesions of the liver.

Citations

Citations to this article as recorded by  Crossref logo
  • An overview of case reports and case series of pulmonary actinomycosis mimicking lung cancer: a scoping review
    Amin Khoshbayan, Nour Amirmozafari, Shiva Mirkalantari
    Frontiers in Medicine.2024;[Epub]     CrossRef
  • Abdominal actinomycosis presented as acute abdomen with intra-abdominal multiple tumors: A case report
    Mohammad Reza Maghsoudi, Mohammad Azizmanesh, Javad Karimi Rozveh, Pouria Chaghamirzayi
    International Journal of Surgery Case Reports.2024; 122: 110113.     CrossRef
  • Primary Hepatic Actinomycosis Mimicking Hepatic Malignancy
    Yong-Kyu Chung, Bo-Hyun Jung, Hee-Jung Wang
    The Korean Journal of Gastroenterology.2022; 79(1): 45.     CrossRef
  • Abdominopelvic Actinomycosis—The Diagnostic and Therapeutic Challenge of the Most Misdiagnosed Disease
    Alin Mihai Vasilescu, Eugen Târcoveanu, Cristian Lupascu, Mihaela Blaj, Corina Lupascu Ursulescu, Costel Bradea
    Life.2022; 12(3): 447.     CrossRef
  • Primary liver actinomycosis in a pediatric patient: A case report and literature review
    Zi-Jian Liang, Jian-Kun Liang, Yun-Pei Chen, Zhen Chen, Yong Wang
    World Journal of Clinical Cases.2021; 9(20): 5717.     CrossRef
  • A systematic review of case reports of hepatic actinomycosis
    Zahra Chegini, Mojtaba Didehdar, Seidamir Pasha Tabaeian, Amin Khoshbayan, Aref Shariati
    Orphanet Journal of Rare Diseases.2021;[Epub]     CrossRef
  • Primary hepatic actinomycosis mimicking liver tumour
    Qi‐Qiang Zeng, Xiang‐Wu Zheng, Qun‐Ji Wang, Zheng‐Ping Yu, Qi‐Yu Zhang
    ANZ Journal of Surgery.2018;[Epub]     CrossRef
  • Hepatic actinomycosis with immunoglobulin G4-related liver disease
    Joo Hyung Lee, Hyung Sun Kim, Ji Sub Kim, Dong Ki Lee, Jin Hong Lim
    Medicine.2018; 97(24): e11146.     CrossRef
  • A Rare Thermophilic Bug in Complicated Diverticular Abscess
    Kyawzaw Lin, Sithu Lin, Aung Naing Lin, Thinzar Lin, Zin Mar Htun, Madhavi Reddy
    Case Reports in Gastroenterology.2017; 11(3): 569.     CrossRef
  • 11,906 View
  • 111 Download
  • 10 Web of Science
  • Crossref

Original Articles

Hepatic neoplasm

Fibroblast growth factor receptor isotype expression and its association with overall survival in patients with hepatocellular carcinoma
Hyo Jeong Lee, Hyo Jeong Kang, Kang Mo Kim, Eun Sil Yu, Ki Hun Kim, Seung-Mi Kim, Tae Won Kim, Ju Hyun Shim, Young-Suk Lim, Han Chu Lee, Young-Hwa Chung, Yung Sang Lee
Clin Mol Hepatol 2015;21(1):60-70.
Published online March 25, 2015
DOI: https://doi.org/10.3350/cmh.2015.21.1.60
Background/Aims

Fibroblast growth factor signaling is involved in hepatocarcinogenesis. The aim of this study was to determine the fibroblast growth factor receptor (FGFR) isotype expression in hepatocellular carcinoma (HCC) and neighboring nonneoplastic liver tissue, and elucidate its prognostic implications.

Methods

Immunohistochemical staining of FGFR1, -2, -3, and -4 was performed in the HCCs and paired neighboring nonneoplastic liver tissue of 870 HCC patients who underwent hepatic resection. Of these, clinical data for 153 patients who underwent curative resection as a primary therapy were reviewed, and the relationship between FGFR isotype expression and overall survival was evaluated (development set). This association was also validated in 73 independent samples (validation set) by Western blot analysis.

Results

FGFR1, -2, -3, and -4 were expressed in 5.3%, 11.1%, 3.8%, and 52.7% of HCCs, respectively. Among the development set of 153 patients, FGFR2 positivity in HCC was associated with a significantly shorter overall survival (5-year survival rate, 35.3% vs. 61.8%; P=0.02). FGFR2 expression in HCC was an independent predictor of a poor postsurgical prognosis (hazard ratio, 2.10; P=0.02) in the development set. However, the corresponding findings were not statistically significant in the validation set.

Conclusions

FGFR2 expression in HCC could be a prognostic indicator of postsurgical survival.

Citations

Citations to this article as recorded by  Crossref logo
  • Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies
    Giovanni Brandi, Valeria Relli, Marzia Deserti, Andrea Palloni, Valentina Indio, Annalisa Astolfi, Salvatore Serravalle, Alessandro Mattiaccio, Francesco Vasuri, Deborah Malvi, Chiara Deiana, Maria Abbondanza Pantaleo, Matteo Cescon, Alessandro Rizzo, Mas
    Scientific Reports.2024;[Epub]     CrossRef
  • Evolving therapeutic landscape of advanced hepatocellular carcinoma
    Chen Yang, Hailin Zhang, Linmeng Zhang, Andrew X. Zhu, René Bernards, Wenxin Qin, Cun Wang
    Nature Reviews Gastroenterology & Hepatology.2023; 20(4): 203.     CrossRef
  • Dietary Fat Composition Affects Hepatic Angiogenesis and Lymphangiogenesis in Hepatitis C Virus Core Gene Transgenic Mice
    Pan Diao, Yaping Wang, Fangping Jia, Xiaojing Wang, Xiao Hu, Takefumi Kimura, Yoshiko Sato, Kyoji Moriya, Kazuhiko Koike, Jun Nakayama, Naoki Tanaka
    Liver Cancer.2023; 12(1): 57.     CrossRef
  • Genomic Relevance of FGFR2 on the Prognosis of HCV-Induced Hepatocellular Carcinoma Patients
    Walizeb Khan, Washaakh Ahmad, Anwar M. Hashem, Shadi Zakai, Shafiul Haque, Muhammad Faraz Arshad Malik, Steve Harakeh, Farhan Haq
    Journal of Clinical Medicine.2022; 11(11): 3093.     CrossRef
  • Prognostic Role of Molecular and Imaging Biomarkers for Predicting Advanced Hepatocellular Carcinoma Treatment Efficacy
    Lucia Cerrito, Maria Elena Ainora, Carolina Mosoni, Raffaele Borriello, Antonio Gasbarrini, Maria Assunta Zocco
    Cancers.2022; 14(19): 4647.     CrossRef
  • AZD4547 and the Alleviation of Hepatoma Cell Sorafenib Resistance via the Promotion of Autophagy
    Yun Feng, Dan Zhang, Gaixia He, Yaping Liu, Yan Zhao, Xiaoyang Ren, Huanhuan Sun, Guifang Lu, Zhiyong Zhang, Li Ren, Yan Yin, Hongxia Li, Shuixiang He
    Anti-Cancer Agents in Medicinal Chemistry.2022; 22(18): 3107.     CrossRef
  • Combination of molecularly targeted therapies and immune checkpoint inhibitors in the new era of unresectable hepatocellular carcinoma treatment
    Ze-Long Liu, Jing-Hua Liu, Daniel Staiculescu, Jiang Chen
    Therapeutic Advances in Medical Oncology.2021;[Epub]     CrossRef
  • Fibroblast growth factor signaling in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Paving the way to hepatocellular carcinoma
    Matthias Ocker
    World Journal of Gastroenterology.2020; 26(3): 279.     CrossRef
  • Tumor-Stroma Crosstalk Enhances REG3A Expressions that Drive the Progression of Hepatocellular Carcinoma
    Yuri Cho, Min Ji Park, Koeun Kim, Jae-Young Park, Jihye Kim, Wonjin Kim, Jung-Hwan Yoon
    International Journal of Molecular Sciences.2020; 21(2): 472.     CrossRef
  • Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular Carcinoma
    Makoto Chuma, Haruki Uojima, Kazushi Numata, Hisashi Hidaka, Hidenori Toyoda, Atsushi Hiraoka, Toshifumi Tada, Shunji Hirose, Masanori Atsukawa, Norio Itokawa, Taeang Arai, Makoto Kako, Takahide Nakazawa, Naohisa Wada, Shuitirou Iwasaki, Yuki Miura, Satos
    Cancers.2020; 12(2): 293.     CrossRef
  • First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody–Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer
    Sung-Bae Kim, Funda Meric-Bernstam, Aparna Kalyan, Aleksei Babich, Rong Liu, Takahiko Tanigawa, Anette Sommer, Motonobu Osada, Frank Reetz, Dirk Laurent, Sabine Wittemer-Rump, Jordan Berlin
    Targeted Oncology.2019; 14(5): 591.     CrossRef
  • The Current Landscape of Systemic Therapies for Advanced Hepatocellular Carcinoma
    Prachi Rana, John Haydek, Anjana Pillai
    Current Hepatology Reports.2019; 18(4): 371.     CrossRef
  • Tumor‐adjacent tissue co‐expression profile analysis reveals pro‐oncogenic ribosomal gene signature for prognosis of resectable hepatocellular carcinoma
    Oleg V. Grinchuk, Surya P. Yenamandra, Ramakrishnan Iyer, Malay Singh, Hwee Kuan Lee, Kiat Hon Lim, Pierce Kah‐Hoe Chow, Vladamir A. Kuznetsov
    Molecular Oncology.2018; 12(1): 89.     CrossRef
  • Molecular therapies and precision medicine for hepatocellular carcinoma
    Josep M. Llovet, Robert Montal, Daniela Sia, Richard S. Finn
    Nature Reviews Clinical Oncology.2018; 15(10): 599.     CrossRef
  • Higher serum interleukin-17A levels as a potential biomarker for predicting early disease progression in patients with hepatitis B virus-associated advanced hepatocellular carcinoma treated with sorafenib
    Hyo Jung Cho, Soon Sun Kim, Ji Sun Nam, Min Jung Oh, Dae Ryong Kang, Jai Keun Kim, Jei Hee Lee, Bohyun Kim, Min Jae Yang, Jae Chul Hwang, Sun Gyo Lim, Sung Jae Shin, Kee Myung Lee, Byung Moo Yoo, Kwang Jae Lee, Sung Won Cho, Jae Youn Cheong
    Cytokine.2017; 95: 118.     CrossRef
  • Prognostic role of fibroblast growth factor receptor 2 in human solid tumors: A systematic review and meta-analysis
    Gang Liu, Disheng Xiong, Rui Xiao, Zhengjie Huang
    Tumor Biology.2017; 39(6): 101042831770742.     CrossRef
  • Hypoxia Enhances Tumor-Stroma Crosstalk that Drives the Progression of Hepatocellular Carcinoma
    Yuri Cho, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Yoon Jun Kim, Chung Yong Kim, Jung-Hwan Yoon
    Digestive Diseases and Sciences.2016; 61(9): 2568.     CrossRef
  • 125I-labeled anti-bFGF monoclonal antibody inhibits growth of hepatocellular carcinoma
    Peng-Hui Hu, Lan-Hong Pan, Patrick Ting-Yat Wong, Wen-Hui Chen, Yan-Qing Yang, Hong Wang, Jun-Jian Xiang, Meng Xu
    World Journal of Gastroenterology.2016; 22(21): 5033.     CrossRef
  • Prognostic roles for fibroblast growth factor receptor family members in malignant peripheral nerve sheath tumor
    Wenya Zhou, Xiaoling Du, Fengju Song, Hong Zheng, Kexin Chen, Wei Zhang, Jilong Yang
    Oncotarget.2016; 7(16): 22234.     CrossRef
  • MicroRNA-126 inhibits tumor proliferation and angiogenesis of hepatocellular carcinoma by down-regulating EGFL7 expression
    Ming-Hua Hu, Chen-Yang Ma, Xiao-Ming Wang, Chen-Dong Ye, Guang-Xian Zhang, Lin Chen, Jin-Guo Wang
    Oncotarget.2016; 7(41): 66922.     CrossRef
  • NGS-based identification of druggable alterations and signaling pathways – hepatocellular carcinoma case report
    E. A. Kotelnikova, M. D. Logacheva, E. R. Nabieva, M. A. Pyatnitskiy, D. V. Vinogradov, A. S. Makarova, A. V. Demin, A. G. Paleeva, O. S. Kremenetskaya, A. A. Penin, A. V. Klepikova, A. S. Kasianov, D. A. Shavochkina, N. E. Kudashkin, Yu. I. Patyutko, N.
    Biopolymers and Cell.2015; 31(6): 436.     CrossRef
  • 11,426 View
  • 135 Download
  • 21 Web of Science
  • Crossref

Viral hepatitis

No association between the IL28B SNP and response to peginterferon plus ribavirin combination treatment in Korean chronic hepatitis C patients
Nae-Yun Heo, Young-Suk Lim, Woochang Lee, Minkyung Oh, Jiyun An, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Han Chu Lee, Yung Sang Lee, Dong Jin Suh
Clin Mol Hepatol 2014;20(2):177-184.
Published online June 30, 2014
DOI: https://doi.org/10.3350/cmh.2014.20.2.177
Background/Aims

There are few available data regarding the association between the single nucleotide polymorphisms (SNPs) of the gene encoding interleukin 28B (IL28B) and a sustained virologic response (SVR) to peginterferon (PEG-IFN) plus ribavirin (RBV) therapy in Korean chronic hepatitis C patients.

Methods

This was a retrospective cohort study of 156 patients with chronic hepatitis C virus (HCV) infection who received combination treatment of PEG-IFN plus RBV. Blood samples from these patients were analyzed to identify the IL28B SNPs at rs12979860, rs12980275, rs8099917, and rs8103142. Association analyses were performed to evaluate the relationships between each IL28B SNP and SVRs.

Results

Seventy six patients with HCV genotype 1 and 80 with genotype non-1 were enrolled. The frequencies of rs12979860 CC and CT genotypes were 90.4% and 9.6%, respectively; those of rs12980275 AA and AG genotypes were 87.2% and 12.8%, respectively; those of rs8099917 TT and TG genotypes were 92.3% and 7.7%, respectively; and those of rs8103142 TT and CT genotypes were 90.4% and 9.6%, respectively. Among the patients with HCV genotype 1, the SVR rates were 69.7% and 80.0% for rs12979860 CC and CT, respectively (P=0.71). Among the HCV genotype non-1 patients, SVR rates were 88.0% and 100% for rs12979860 CC and CT (P=1.00), respectively.

Conclusions

Genotypes of the IL28B SNP that are known to be favorable were present in most of the Korean patients with chronic hepatitis C in this study. Moreover, the IL28B SNP did not influence the SVR rate in either the HCV genotype 1 or non-1 patients. Therefore, IL28B SNP analysis might be not useful for the initial assessment, prediction of treatment outcomes, or treatment decision-making of Korean chronic hepatitis C patients.

Citations

Citations to this article as recorded by  Crossref logo
  • IL28B gene polymorphism rs12979860, but not rs8099917, contributes to the occurrence of chronic HCV infection in Uruguayan patients
    Natalia Echeverría, Daniela Chiodi, Pablo López, Adriana Sanchez Ciceron, Jenniffer Angulo, Marcelo López-Lastra, Paola Silvera, Adrian Canavesi, Carla Bianchi, Valentina Colistro, Juan Cristina, Nelia Hernandez, Pilar Moreno
    Virology Journal.2018;[Epub]     CrossRef
  • The impact of genetic variation in IL28B, IFNL4 and HLA genes on treatment responses against chronic hepatitis C virus infection
    Fatemeh Sakhaee, Morteza Ghazanfari, Farzam Vaziri, Fatemeh Rahimi Jamnani, Mehdi Davari, Safoora Gharibzadeh, Roohollah Fateh, Farid Abdolrahimi, Shahin Pourazar Dizaji, Abolfazl Fateh, Seyed Davar Siadat
    Infection, Genetics and Evolution.2017; 54: 330.     CrossRef
  • Immunological dynamics associated with rapid virological response during the early phase of type I interferon therapy in patients with chronic hepatitis C
    Jae-Won Lee, Won Kim, Eun-Kyung Kwon, Yuri Kim, Hyun Mu Shin, Dong-Hyun Kim, Chan-Ki Min, Ji-Yeob Choi, Won-Woo Lee, Myung-Sik Choi, Byeong Gwan Kim, Nam-Hyuk Cho, Eui-Cheol Shin
    PLOS ONE.2017; 12(6): e0179094.     CrossRef
  • IL28B rs12980275 variant as a predictor of sustained virologic response to pegylated-interferon and ribavirin in chronic hepatitis C patients: A systematic review and meta-analysis
    Hao Zheng, Man Li, Bing Chi, Xiao-xue Wu, Jia Wang, Dian-Wu Liu
    Clinics and Research in Hepatology and Gastroenterology.2015; 39(5): 576.     CrossRef
  • 9,814 View
  • 60 Download
  • 4 Web of Science
  • Crossref

Hepatic neoplasm

Role of 15-hydroxyprostaglandin dehydrogenase down-regulation on the prognosis of hepatocellular carcinoma
Jee Eun Yang, Eunji Park, Hyo Jeong Lee, Hyo Jeong Kang, Kang Mo Kim, Eunsil Yu, Danbi Lee, Ju Hyun Shim, Young-Suk Lim, Han Chu Lee, Young-Hwa Chung, Yung Sang Lee
Clin Mol Hepatol 2014;20(1):28-37.
Published online March 26, 2014
DOI: https://doi.org/10.3350/cmh.2014.20.1.28
Background/Aims

The role of prostaglandin E2 (PGE2) in the modulation of cell growth is well established in colorectal cancer. The aim of this study was to elucidate the significance of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) down-regulation on the prognosis of hepatocellular carcinoma (HCC) patients.

Methods

The expression of 15-PGDH in HCC cell lines and resected HCC tissues was investigated, and the correlation between 15-PGDH expression and HCC cell-line proliferation and patient survival was explored.

Results

The interleukin-1-β-induced suppression of 15-PGDH did not change the proliferation of PLC and Huh-7 cells in the MTS [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay. The induction of 15-PGDH by transfection in HepG2 cells without baseline 15-PGDH expression was suppressed at day 2 of proliferation compared with empty-vector transfection, but there was no difference at day 3. Among the 153 patients who received curative HCC resection between 2003 and 2004 at our institution, 15-PGDH expression was observed in resected HCC tissues in 56 (36.6%), but the 5-year survival rate did not differ from that of the remaining 97 non-15-PGDH-expressing patients (57.1% vs 59.8%; P=0.93). Among 50 patients who exhibited baseline 15-PGDH expression in adjacent nontumor liver tissues, 28 (56%) exhibited a reduction in 15-PGDH expression score in HCC tissues, and there was a trend toward fewer long-term survivors compared with the remaining 22 with the same or increment in their 15-PGDH expression score in HCC tissues.

Conclusions

The prognostic significance of 15-PGDH down-regulation in HCC was not established in this study. However, maintenance of 15-PGDH expression could be a potential therapeutic target for a subgroup of HCC patients with baseline 15-PGDH expression in adjacent nontumor liver tissue.

Citations

Citations to this article as recorded by  Crossref logo
  • The tumor suppressor role and epigenetic regulation of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) in cancer and tumor microenvironment (TME)
    SubbaRao V. Tulimilli, Medha Karnik, Anjali Devi S. Bettadapura, Olga A. Sukocheva, Edmund Tse, Gowthamarajan Kuppusamy, Suma M. Natraj, SubbaRao V. Madhunapantula
    Pharmacology & Therapeutics.2025; 268: 108826.     CrossRef
  • 15-Keto prostaglandin E2 induces heme oxygenase-1 expression through activation of Nrf2 in human colon epithelial CCD 841 CoN cells
    Jeong-Eun Lee, Xiancai Zhong, Ja-Young Lee, Young-Joon Surh, Hye-Kyung Na
    Archives of Biochemistry and Biophysics.2020; 679: 108162.     CrossRef
  • The prostanoid pathway contains potential prognostic markers for glioblastoma
    Alexandros Theodoros Panagopoulos, Renata Nascimento Gomes, Fernando Gonçalves Almeida, Felipe da Costa Souza, José Carlos Esteves Veiga, Anna Nicolaou, Alison Colquhoun
    Prostaglandins & Other Lipid Mediators.2018; 137: 52.     CrossRef
  • 10,491 View
  • 70 Download
  • 3 Web of Science
  • Crossref

Case Report

Drug rash with eosinophilia and systemic symptoms syndrome following cholestatic hepatitis A: a case report
Jihyun An, Joo Ho Lee, Hyojeong Lee, Eunsil Yu, Dan Bi Lee, Ju Hyun Shim, Sunyoung Yoon, Yumi Lee, Soeun Park, Han Chu Lee
Korean J Hepatol 2012;18(1):84-88.
Published online March 22, 2012
DOI: https://doi.org/10.3350/kjhep.2012.18.1.84

Hepatitis A virus (HAV) infections occur predominantly in children, and are usually self-limiting. However, 75-95% of the infections in adults are symptomatic (mostly with jaundice), with the illness symptoms usually persisting for a few weeks. Atypical manifestations include relapsing hepatitis, prolonged cholestasis, and complications involving renal injury. Drug rash with eosinophilia and systemic symptoms (DRESS) syndrome is a severe, drug-induced hypersensitivity reaction characterized by skin rash, fever, lymph-node enlargement, and internal organ involvement. We describe a 22-year-old male who presented with acute kidney injury and was diagnosed with prolonged cholestatic hepatitis A. The patient also developed DRESS syndrome due to antibiotic and/or antiviral treatment. To our knowledge, this is the first report of histopathologically confirmed DRESS syndrome due to antibiotic and/or antiviral treatment following HAV infection with cholestatic features and renal injury.

Citations

Citations to this article as recorded by  Crossref logo
  • Recent advances in hepatitis A virus research and clinical practice guidelines for hepatitis A virus infection in Japan
    Tatsuo Kanda, Reina Sasaki‐Tanaka, Koji Ishii, Ryosuke Suzuki, Jun Inoue, Atsunori Tsuchiya, Shingo Nakamoto, Ryuzo Abe, Keiichi Fujiwara, Osamu Yokosuka, Tian‐Cheng Li, Satoshi Kunita, Hiroshi Yotsuyanagi, Hiroaki Okamoto
    Hepatology Research.2024; 54(1): 4.     CrossRef
  • DRESS syndrome with cholecystitis in a child: A case report and literature review
    Ferdaous Chahed, Najah Ben Fadhel, Haifa Ben Romdhane, Zohra Chadli, Habib Besbes, Naceur Boughattas, Nadia Ben Fredj, Karim Aouam
    Therapies.2022; 77(5): 622.     CrossRef
  • Characterizing DRESS syndrome recurrence: a systematic review
    Ajay N. Sharma, Samantha Shwe, Vignesh Ravi, Melanie Miller, Natasha A. Mesinkovska, Nathan W. Rojek, Scott Worswick
    Archives of Dermatological Research.2021; 314(8): 721.     CrossRef
  • Mechanisms of Severe Cutaneous Adverse Reactions: Recent Advances
    Teresa Bellón
    Drug Safety.2019; 42(8): 973.     CrossRef
  • Variation of clinical manifestations according to culprit drugs in DRESS syndrome
    Da Woon Sim, Ji Eun Yu, Jiung Jeong, Jae‐Woo Jung, Hye‐Ryun Kang, Dong Yoon Kang, Young Min Ye, Young‐Koo Jee, Sujeong Kim, Jung‐Won Park, Min Gyu Kang, Sae Hoon Kim, Hye‐Kyung Park, Min‐Suk Yang, Gyu‐Young Hur, Jun Kyu Lee, Jeong‐Hee Choi, Yong Eun Kwon,
    Pharmacoepidemiology and Drug Safety.2019; 28(6): 840.     CrossRef
  • Allopurinol-induced DRESS syndrome mimicking biliary obstruction
    Hyung Gyu Choi, Junsu Byun, Chae Ho Moon, Jong Ho Yoon, Ki Young Yang, Su Cheol Park, Chul Ju Han
    Clinical and Molecular Hepatology.2014; 20(1): 71.     CrossRef
  • Dress Syndrome Induced by Sulphasalazine
    K. Pałgan, Z. Bartuzi
    European Journal of Inflammation.2014; 12(1): 187.     CrossRef
  • Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)
    S. Ständer, D. Metze, T. Luger, T. Schwarz
    Der Hautarzt.2013; 64(8): 611.     CrossRef
  • 9,604 View
  • 61 Download
  • Crossref
Original Article
Treatment and clinical outcome of needle-track seeding from hepatocellular carcinoma
Dong-Won Ahn, Ju Hyun Shim, Jung-Hwan Yoon, Chung Yong Kim, Hyo-Suk Lee, Yeong Tae Kim, Yoon Jun Kim
Korean J Hepatol 2011;17(2):106-112.
Published online June 23, 2011
DOI: https://doi.org/10.3350/kjhep.2011.17.2.106
Background/Aims

Needle-track seeding is a rare but important complication of diagnostic and therapeutic ultrasound (US)-guided procedures in hepatocellular carcinoma (HCC). We examined the frequency of needle-track seeding after US-guided percutaneous ethanol injection (PEI), fine-needle aspiration biopsy (FNAB), and percutaneous transhepatic biliary drainage (PTBD) in order to determine the appropriate treatment for needle-track seeding and its clinical outcome.

Methods

We analyzed the clinical characteristics and treatment outcomes in eight patients who experienced needle-track seeding from HCC after an US-guided procedure (FNAB, PEI, or PTBD) between January 1990 and July 2004.

Results

Seven (0.14%) of 5,092 patients who experienced needle-track seeding (2 after PEI, 4 after FNAB, and 1 after PTBD) during the study period and 1 other patient who experienced needle-track seeding recently were recruited for this study. Two of the eight patients underwent mass excision and the other six patients underwent en-bloc wide excision for the needle-track seeding. Tumors recurred in the needle-tracks in both patients who underwent mass excision but not in the six patients who underwent en-bloc wide excision. Mortality occurred in three patients who experienced the recurrence and progression of intrahepatic HCC.

Conclusions

The incidence of needle-track seeding after US-guided procedures in HCC was 0.14%. En-bloc wide excision seems to be the optimal treatment for minimizing the probability of tumor recurrence due to needle-track seeding.

Citations

Citations to this article as recorded by  Crossref logo
  • Use of Albumin In Situ Hybridization to Diagnose Cutaneous Metastatic Hepatocellular Carcinoma With Poorly Differentiated Features: A Case Report and Review of the Literature
    Andrew J. Gauger, Aofei Li, Mike Fritz, Terrence M. Katona, Ahmed K. Alomari
    The American Journal of Dermatopathology.2025; 47(3): 211.     CrossRef
  • Combined Neuroendocrine Carcinoma and Hepatocellular Carcinoma of the Liver: Systematic Literature Review Suggests Implementing Biological Characterization to Optimize Therapeutic Strategy
    Daniela Sambataro, Sandro Bellavia, Paolo Di Mattia, Danilo Centonze, Carmela Emmanuele, Annalisa Bonasera, Giuseppe Caputo, Andrea Maria Onofrio Quattrocchi, Ernesto Vinci, Vittorio Gebbia, Maria Rosaria Valerio
    Cancers.2025; 17(7): 1074.     CrossRef
  • Fibrolamellar Hepatocellular Carcinoma (FLHCC) in a Young Patient Presenting With Nausea and Vomiting After a Greasy Meal
    Mohamed Ismail , Sahiba Singh, Menna-Allah Elaskandrany , David s Kim, Yazan Abboud, Michael Bebawy, Abena Oduro, Ritik mahaveer Goyal, Omar Mohamed , Weizheng Wang
    Cureus.2024;[Epub]     CrossRef
  • Tumor seeding across specialties: a systematic review
    Pavel Kipnis, Diya Ramanathan, Richard Hoehn, Ashok R. Jethwa, Daniel W. Karakla, Bethany Rohr, Christopher M. Sutter, Jonathan R. Mark, Sobia F. Khaja, Shawn Li, Jason Thuener, Bryan T. Carroll
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Safety of percutaneous, image-guided biopsy of hepatocellular carcinoma with and without concurrent ablation
    Justin R. Tse, Kevin Terashima, Luyao Shen, Justin P. McWilliams, David S. K. Lu, Steven S. Raman
    Abdominal Radiology.2022; 47(8): 2640.     CrossRef
  • Effect of Autotransfusion in HCC Surgery on Survival and Recurrence: A Systematic Review and Meta-Analysis
    Anastasia Murtha-Lemekhova, Juri Fuchs, Emil Ritscher, Katrin Hoffmann
    Cancers.2022; 14(19): 4837.     CrossRef
  • Biopsy for advanced hepatocellular carcinoma: results of a multicentre UK audit
    Alexa Childs, Nekisa Zakeri, Yuk Ting Ma, Joanne O’Rourke, Paul Ross, Essam Hashem, Richard A. Hubner, Kimberley Hockenhull, Chinenye Iwuji, Sam Khan, Daniel H. Palmer, Joanna Connor, Daniel Swinson, Suzanne Darby, Chiara Braconi, Tom Roques, Dominic Yu,
    British Journal of Cancer.2021; 125(10): 1350.     CrossRef
  • S3538 Needle Track Seeding in a Patient With Hepatocellular Carcinoma
    Sara Goff, Bhishak Kamat, Alyssa Goldbach, Shqiponja Hajdinaj, Joseph Panaro
    American Journal of Gastroenterology.2020; 115(1): S16.     CrossRef
  • ACR Appropriateness Criteria® Liver Lesion-Initial Characterization
    Victoria Chernyak, Jeanne M. Horowitz, Ihab R. Kamel, Hina Arif-Tiwari, Mustafa R. Bashir, Brooks D. Cash, James Farrell, Alan Goldstein, Joseph R. Grajo, Samir Gupta, Nicole M. Hindman, Aya Kamaya, Michelle M. McNamara, Kristin K. Porter, Lilja Bjork. So
    Journal of the American College of Radiology.2020; 17(11): S429.     CrossRef
  • ЗАСТОСУВАННЯ ПЕРКУТАННОЇ ХІМІЧНОЇ АБЛЯЦІЇ В ЛІКУВАННІ ПАЦІЄНТІВ З ГЕПАТОЦЕЛЮЛЯРНОЮ КАРЦИНОМОЮ
    Lyudmila Levchenko, Yelyzaveta Kozachuk, Sergey Zemskov
    The Ukrainian Scientific Medical Youth Journal.2020; 116(2): 33.     CrossRef
  • Role of liver biopsy in hepatocellular carcinoma
    Luca Di Tommaso, Marco Spadaccini, Matteo Donadon, Nicola Personeni, Abubaker Elamin, Alessio Aghemo, Ana Lleo
    World Journal of Gastroenterology.2019; 25(40): 6041.     CrossRef
  • Rate of seeding with biopsies and ablations of hepatocellular carcinoma: A retrospective cohort study
    Jean‐Luc Szpakowski, Todd E. Drasin, Liisa L. Lyon
    Hepatology Communications.2017; 1(9): 841.     CrossRef
  • Response to transarterial chemoembolization may serve as selection criteria for hepatocellular carcinoma liver transplantation
    Jianyong Lei, Jinjing Zhong, Yefang Luo, Lunan Yan, Jinqiang Zhu, Wentao Wang, Bo Li, Tianfu Wen, Jiaying Yang
    Oncotarget.2017; 8(53): 91328.     CrossRef
  • Percutaneous Tumor Ablation
    Xiaofeng He, Yueyong Xiao, Xiao Zhang, Peng Du, Xin Zhang, Jie Li, Yunxia An, Patrick Le Pivert
    Technology in Cancer Research & Treatment.2016; 15(4): 597.     CrossRef
  • Metástasis cutánea de hepatocarcinoma tras procedimientos percutáneos
    F.J. de León, M.M. Blanes, M.P. Albares, L. Berbegal
    Actas Dermo-Sifiliográficas.2015; 106(5): 440.     CrossRef
  • Cutaneous Metastasis From Hepatocellular Carcinoma After a Percutaneous Interventional Procedure
    F.J. de León, M.M. Blanes, M.P. Albares, L. Berbegal
    Actas Dermo-Sifiliográficas (English Edition).2015; 106(5): 440.     CrossRef
  • Needle tract seeding: An avoidable complication
    Ruchita Tyagi, Pranab Dey
    Diagnostic Cytopathology.2014; 42(7): 636.     CrossRef
  • Parietal and peritoneal localizations of hepatocellular carcinoma: is there a place for a curative surgery?
    Nazario Portolani, Gian Luca Baiocchi, Federico Gheza, Sarah Molfino, Daniele Lomiento, Stefano Maria Giulini
    World Journal of Surgical Oncology.2014;[Epub]     CrossRef
  • Effectiveness and Complications of Ultrasound Guided Fine Needle Aspiration for Primary Liver Cancer in a Chinese Population with Serum α-Fetoprotein Levels ≤200 ng/ml - A Study Based on 4,312 Patients
    Qi-wen Chen, Chien-shan Cheng, Hao Chen, Zhou-yu Ning, Shi-feng Tang, Xun Zhang, Xiao-yan Zhu, Sonya Vargulick, Ye-hua Shen, Yong-qiang Hua, Jing Xie, Wei-dong Shi, Hui-feng Gao, Li-tao Xu, Lan-yun Feng, Jun-hua Lin, Zhen Chen, Lu-ming Liu, Bo Ping, Zhi-q
    PLoS ONE.2014; 9(8): e101536.     CrossRef
  • Consequences of needle tract seeding of hepatocellular cancer after liver transplant
    Kristi T. Lopez, Scott K. Kuwada, Linda L. Wong
    Clinical Transplantation.2013;[Epub]     CrossRef
  • Percutaneous interventional procedures in an era of liver transplantation
    Young Seok Kim
    The Korean Journal of Hepatology.2011; 17(2): 96.     CrossRef
  • 9,342 View
  • 57 Download
  • Crossref